<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3848</journal-id><journal-id journal-id-type="pmc-domain">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title-group><journal-title>bioRxiv</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10369889</article-id><article-id pub-id-type="pmcid-ver">PMC10369889.2</article-id><article-id pub-id-type="pmcaid">10369889</article-id><article-id pub-id-type="pmcaiid">10760330</article-id><article-id pub-id-type="pmid">37502871</article-id><article-id pub-id-type="doi">10.1101/2023.07.10.548412</article-id><article-version-alternatives><article-version article-version-type="pmc-version">2</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1417-9200</contrib-id><name name-style="western"><surname>Pineda</surname><given-names initials="JMB">Jose Mario Bello</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8046-1063</contrib-id><name name-style="western"><surname>Bradley</surname><given-names initials="RK">Robert K.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA</aff><aff id="A2"><label>2</label>Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA</aff><aff id="A3"><label>3</label>Department of Genome Sciences, University of Washington, Seattle, WA, USA</aff><aff id="A4"><label>4</label>Medical Scientist Training Program, University of Washington, Seattle, WA, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2">J.M.B.P. and R.K.B. designed the study, analyzed the data, and wrote the paper.</p></fn><corresp id="CR1"><label>*</label>Correspondence: <email>rbradley@fredhutch.org</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>12</month><year>2023</year></pub-date><issue-id pub-id-type="pmc-issue-id">441577</issue-id><elocation-id>2023.07.10.548412</elocation-id><pub-history><event event-type="pmc-release"><date><day>02</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-04 00:25:13.770"><day>04</day><month>06</month><year>2024</year></date></event><event event-type="original-publication" specific-use="live"><article-id pub-id-type="pmcaiid">10369889</article-id><article-version>1</article-version><pub-date><day>11</day><month>07</month><year>2023</year></pub-date></event><event event-type="pmc-published-version" specific-use="live"><article-id pub-id-type="pmcaiid">10369889</article-id><article-version>1</article-version><pub-date><day>11</day><month>07</month><year>2023</year></pub-date></event><event event-type="pmc-published-version" specific-use="live"><article-id pub-id-type="pmcaiid">10760330</article-id><article-version>2</article-version><pub-date><day>29</day><month>12</month><year>2023</year></pub-date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihpp-2023.07.10.548412v2.pdf"/><self-uri content-type="pdf">nihpp-2023.07.10.548412.pdf</self-uri><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="published-article" xml:lang="en" xlink:title="research-article" journal-id="eLife" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11147511"><article-title>DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers</article-title><volume>12</volume><date><day>3</day><month>6</month><year>2024</year></date><elocation-id>RP89017</elocation-id><source>eLife</source><pub-id pub-id-type="doi">10.7554/eLife.89017</pub-id><pub-id pub-id-type="pmcid">PMC11147511</pub-id><pub-id pub-id-type="pmid">38829686</pub-id></related-article><abstract id="ABS1"><p id="P3">Cancer immune evasion contributes to checkpoint immunotherapy failure in many patients with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized as a suppressor of interferon-&#947; signaling and antigen presentation that is aberrantly expressed in a small subset of primary tumors. Here, we report that <italic toggle="yes">DUX4</italic> expression is a common feature of metastatic tumors, with ~10&#8211;50% of advanced bladder, breast, kidney, prostate, and skin cancers expressing <italic toggle="yes">DUX4</italic>. <italic toggle="yes">DUX4</italic> expression is significantly associated with immune cell exclusion and decreased objective response to PD-L1 blockade in a large cohort of urothelial carcinoma patients. <italic toggle="yes">DUX4</italic> expression is a significant predictor of survival even after accounting for tumor mutational burden and other molecular and clinical features in this cohort, with <italic toggle="yes">DUX4</italic> expression associated with a median reduction in survival of over one year. Our data motivate future attempts to develop DUX4 as a biomarker and therapeutic target for checkpoint immunotherapy resistance.</p></abstract><kwd-group><kwd>DUX4</kwd><kwd>immune checkpoint inhibition</kwd><kwd>antigen presentation</kwd><kwd>metastatic cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p id="P6">Immune checkpoint inhibition (ICI) therapy utilizes immunomodulatory monoclonal antibodies to stimulate patient anti-tumor immune responses. Blockade of T cell co-inhibitory receptors, such as CTLA-4 and the PD-1/PD-L1 axis, has achieved major success in the treatment of diverse metastatic cancers compared to first-line chemotherapy (<xref rid="R22" ref-type="bibr">Doki et al., 2022</xref>; <xref rid="R36" ref-type="bibr">Hellmann et al., 2019</xref>; <xref rid="R55" ref-type="bibr">Klein et al., 2020</xref>; <xref rid="R59" ref-type="bibr">Larkin et al., 2019</xref>; <xref rid="R78" ref-type="bibr">Motzer et al., 2020</xref>; <xref rid="R107" ref-type="bibr">Stein et al., 2022</xref>). However, a majority of advanced cancer patients fail to respond to ICI due to de novo or acquired resistance, the mechanistic bases of which remain incompletely understood.</p><p id="P7">Diverse mechanisms modulate sensitivity and resistance to immune checkpoint inhibition (<xref rid="R51" ref-type="bibr">Kalbasi &amp; Ribas, 2020</xref>). These mechanisms include defects in MHC class I-mediated antigen presentation due to loss of <italic toggle="yes">B2M</italic> or <italic toggle="yes">HLA</italic> (<xref rid="R31" ref-type="bibr">Grasso et al., 2018</xref>; <xref rid="R61" ref-type="bibr">Lee et al., 2020</xref>; <xref rid="R73" ref-type="bibr">McGranahan et al., 2016</xref>; <xref rid="R95" ref-type="bibr">Sade-Feldman et al., 2017</xref>; <xref rid="R110" ref-type="bibr">Sucker et al., 2014</xref>; <xref rid="R121" ref-type="bibr">Wolf et al., 2019</xref>), <italic toggle="yes">PTEN</italic> and <italic toggle="yes">LSD1</italic> inactivation, which sensitizes tumor cells to type I interferon signaling (<xref rid="R64" ref-type="bibr">S. Li et al., 2016</xref>; <xref rid="R84" ref-type="bibr">Peng et al., 2016</xref>; <xref rid="R100" ref-type="bibr">Sheng et al., 2018</xref>), T cell dysfunction (<xref rid="R49" ref-type="bibr">Jiang et al., 2018</xref>), presence of specific T cell populations in the tumor microenvironment (<xref rid="R27" ref-type="bibr">Gide et al., 2019</xref>), and active WNT&#8211;&#946;-catenin signaling (<xref rid="R104" ref-type="bibr">Spranger et al., 2015</xref>). MAPK signaling in <italic toggle="yes">BRAF</italic>-mutated melanomas and CDK4/CDK6 activity have also been implicated in reduced ICI efficacy, and combination treatment with a MAPK/CDK inhibitor improves response to checkpoint blockade (<xref rid="R4" ref-type="bibr">Ascierto et al., 2019</xref>; <xref rid="R19" ref-type="bibr">Deng et al., 2018</xref>; <xref rid="R23" ref-type="bibr">Ebert et al., 2016</xref>; <xref rid="R29" ref-type="bibr">Goel et al., 2017</xref>; <xref rid="R48" ref-type="bibr">Jerby-Arnon et al., 2018</xref>; <xref rid="R89" ref-type="bibr">Ribas et al., 2019</xref>; <xref rid="R96" ref-type="bibr">Schaer et al., 2018</xref>; <xref rid="R112" ref-type="bibr">Sullivan et al., 2019</xref>).</p><p id="P8">Tumor cell-intrinsic interferon-gamma (IFN-&#947;) signaling is particularly important in anti-tumor immunity. This pathway induces expression of genes involved in MHC class I-mediated antigen processing and presentation, which include genes encoding the TAP1/TAP2 transporters, components of the immunoproteasome, HLA proteins, and B2M (<xref rid="R1" ref-type="bibr">Alspach et al., 2019</xref>). Thus, suppression of IFN-&#947; activity promotes tumor immune evasion and decreased CD8<sup>+</sup> T cell activation. Indeed, decreased ICI efficacy was observed in patients with tumors harboring inactivating mutations in IFN-&#947; pathway genes such as <italic toggle="yes">JAK1</italic> and <italic toggle="yes">JAK2</italic> (<xref rid="R26" ref-type="bibr">Gao et al., 2016</xref>; <xref rid="R81" ref-type="bibr">Nguyen et al., 2021</xref>; <xref rid="R109" ref-type="bibr">Sucker et al., 2017</xref>; Zaretsky et al., 2016). Similarly, a recent study reported a splicing-augmenting mutation in <italic toggle="yes">JAK3</italic>, linked to decreased <italic toggle="yes">JAK3</italic> expression levels, as a potential mechanism of resistance in a patient with metastatic melanoma treated with anti-PD-1 and anti-CTLA-4 combination therapy (<xref rid="R80" ref-type="bibr">Newell et al., 2022</xref>).</p><p id="P9">Some cancers exhibit aberrant expression of embryonic DUX transcription factors. For instance, <italic toggle="yes">DUXB</italic> is expressed in diverse primary malignancies, most notably in testicular germ cell and breast carcinomas (<xref rid="R86" ref-type="bibr">Preussner et al., 2018</xref>). Recent work from our group and others showed that <italic toggle="yes">DUX4</italic> is expressed in a small subset of primary tumors, where it suppresses tumor cell antigen presentation and response to IFN-&#947; signaling (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>; <xref rid="R103" ref-type="bibr">Spens et al., 2023</xref>). We additionally observed signals that <italic toggle="yes">DUX4</italic> expression was associated with reduced survival following response to anti-CTLA-4 or anti-PD-1 in melanoma; however, those analyses relied upon two small cohorts (n = 27 or 41 patients), limiting the statistical power of our conclusions.</p><p id="P10">In its native embryonic context, DUX4 initializes human zygotic genome activation. <italic toggle="yes">DUX4</italic> expression levels peak at the 4-cell stage of the cleavage embryo; <italic toggle="yes">DUX4</italic> is then immediately silenced via epigenetic repression of the D4Z4 repeat array that contains the <italic toggle="yes">DUX4</italic> gene (<xref rid="R18" ref-type="bibr">de Iaco et al., 2017</xref>; <xref rid="R37" ref-type="bibr">Hendrickson et al., 2017</xref>; <xref rid="R38" ref-type="bibr">Himeda &amp; Jones, 2019</xref>; <xref rid="R111" ref-type="bibr">Sugie et al., 2020</xref>; <xref rid="R118" ref-type="bibr">Whiddon et al., 2017</xref>). Aside from select sites of immune privilege such as the testis, <italic toggle="yes">DUX4</italic> remains silenced in adult somatic tissues (<xref rid="R17" ref-type="bibr">Das &amp; Chadwick, 2016</xref>; <xref rid="R102" ref-type="bibr">Snider et al., 2010</xref>).</p><p id="P11">Since <italic toggle="yes">DUX4</italic> expression in cancer cells suppresses MHC class I-mediated antigen presentation (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>), we hypothesized that <italic toggle="yes">DUX4</italic> expression might be particularly common in the setting of metastatic disease (versus the primary cancers that we studied previously), where immune evasion is particularly important. We therefore analyzed several large cohorts of patients with different metastatic cancers to determine the frequency of <italic toggle="yes">DUX4</italic> expression in advanced disease. We additionally rigorously tested the potential importance of <italic toggle="yes">DUX4</italic> expression for patient response to ICI in a well-powered cohort.</p></sec><sec id="S2"><title>RESULTS</title><sec id="S3"><title><italic toggle="yes">DUX4</italic> is commonly expressed in diverse metastatic cancer types</title><p id="P12">To assess the prevalence of <italic toggle="yes">DUX4</italic>-expressing human malignancies, we performed a large-scale analysis of publicly available RNA-seq data across diverse cancer types (<xref rid="F1" ref-type="fig">Fig. 1A</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S1A</xref>). The majority of the cohorts in The Cancer Genome Atlas (TCGA) are most commonly comprised of primary samples and local metastases. We found that <italic toggle="yes">DUX4</italic> expression is a particularly common feature across advanced-stage cancers, with 10&#8211;50% of cancer samples (depending upon cancer type) displaying <italic toggle="yes">DUX4</italic> expression levels comparable to or greater than those observed in the early embryo, where expression of the highly stereotyped DUX4-induced gene expression program is observed (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>; <xref rid="R37" ref-type="bibr">Hendrickson et al., 2017</xref>). A markedly higher proportion of advanced metastatic cancers express <italic toggle="yes">DUX4</italic>&#8212;and tend to have higher absolute <italic toggle="yes">DUX4</italic> expression levels&#8212;than do their TCGA cancer counterparts (<xref rid="F1" ref-type="fig">Fig. 1B</xref>&#8211;<xref rid="F1" ref-type="fig">C</xref>).</p><p id="P13">We sought to determine if the <italic toggle="yes">DUX4</italic> transcripts in metastatic cancers express the entire coding sequence or only a portion thereof, as expressed <italic toggle="yes">DUX4</italic> truncations due to genomic rearrangements are frequent oncogenic drivers in particular cancer subtypes, most notably undifferentiated round cell sarcomas (CIC-DUX4 oncoprotein) (<xref rid="R3" ref-type="bibr">Antonescu et al., 2017</xref>; <xref rid="R14" ref-type="bibr">Choi et al., 2013</xref>; <xref rid="R30" ref-type="bibr">Graham et al., 2012</xref>; <xref rid="R46" ref-type="bibr">Italiano et al., 2012</xref>; <xref rid="R54" ref-type="bibr">Kawamura-Saito et al., 2006</xref>; <xref rid="R124" ref-type="bibr">Yoshida et al., 2016</xref>; <xref rid="R125" ref-type="bibr">Yoshimoto et al., 2009</xref>) and adolescent B-cell acute lymphoblastic leukemia (ALL) (<xref rid="R65" ref-type="bibr">Lilljebj&#246;rn et al., 2016</xref>; <xref rid="R67" ref-type="bibr">Liu et al., 2016</xref>; <xref rid="R87" ref-type="bibr">Qian et al., 2017</xref>; <xref rid="R123" ref-type="bibr">Yasuda et al., 2016</xref>). We aligned RNA-seq reads to the <italic toggle="yes">DUX4</italic> cDNA sequence and examined read coverage over the open reading frame. Resembling the cleavage stage embryo and <italic toggle="yes">DUX4</italic>-expressing primary cancers, <italic toggle="yes">DUX4-</italic>positive metastatic tumors transcribe the full-length coding region. In contrast, B-cell ALL exhibited the expected C-terminal truncation due to <italic toggle="yes">DUX4</italic> fusion with the <italic toggle="yes">IGH</italic> locus (<xref rid="F1" ref-type="fig">Fig. 1D</xref>).</p><p id="P14">Since <italic toggle="yes">DUX4</italic> is typically silent in most healthy tissue contexts outside the cleavage-stage embryo (<xref rid="R17" ref-type="bibr">Das &amp; Chadwick, 2016</xref>; <xref rid="R102" ref-type="bibr">Snider et al., 2010</xref>), we investigated if artifacts related to sequencing and sample processing could account for the observed high rates of <italic toggle="yes">DUX4</italic> expression in metastatic versus primary cancers. We were particularly interested in determining whether the method of RNA recovery influenced <italic toggle="yes">DUX4</italic> detection rate, as the analyzed metastatic cohorts frequently relied upon formalin-fixed samples rather than the frozen samples frequently used by TCGA. We took advantage of a cohort of patients with diverse metastatic tumor types for which patient-matched flash-frozen and formalin-fixed metastatic tumor samples were analyzed by RNA-seq (via poly(A)-selection and hybrid probe capture sequencing library preparations, respectively) (<xref rid="R90" ref-type="bibr">D. R. Robinson et al., 2017</xref>). Our re-analysis revealed that <italic toggle="yes">DUX4</italic> expression is readily detectable and quantifiable for both sample and library preparation methods. <italic toggle="yes">DUX4</italic> transcript levels in the majority of the sequenced samples were higher in poly(A)-selected sequencing than were the analogous measurements obtained from hybrid capture (<xref rid="SD1" ref-type="supplementary-material">Fig. S1B</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">C</xref>). These data demonstrate that the high rates of <italic toggle="yes">DUX4</italic> expression that we observed across metastatic cancer cohorts reflect true <italic toggle="yes">DUX4</italic> expression rather than technical biases introduced by studying formalin-fixed tissues and are consistent with expression of a polyadenylated <italic toggle="yes">DUX4</italic> transcript in both primary and metastatic cancers.</p></sec><sec id="S4"><title><italic toggle="yes">DUX4</italic> expression is associated with immune cell exclusion</title><p id="P15">We next sought to assess the downstream consequences of <italic toggle="yes">DUX4</italic> expression in metastatic cancers. We focused on urothelial cancers for two reasons. First, urothelial cancers exhibited one of the highest frequencies of <italic toggle="yes">DUX4</italic> expression (54% of patients) in any of the five metastatic cancer cohorts that we analyzed, suggesting that DUX4 could be particularly important in that tumor type. Second, pretreatment samples from 347 patients enrolled in the IMvigor210 trial, a phase 2 trial of anti-PD-L1 (atezolizumab) therapy with advanced urothelial carcinoma, were subject to transcriptome profiling by RNA-seq as well as immunohistochemical analysis, enabling us to conduct comprehensive studies of the association between <italic toggle="yes">DUX4</italic> expression, the global transcriptome, and immunophenotypes in a well-powered cohort (<xref rid="R6" ref-type="bibr">Balar et al., 2017</xref>; <xref rid="R71" ref-type="bibr">Mariathasan et al., 2018</xref>; <xref rid="R93" ref-type="bibr">Rosenberg et al., 2016</xref>).</p><p id="P16">We examined associations between global gene expression profiles and <italic toggle="yes">DUX4</italic> expression in this advanced urothelial carcinoma cohort. We performed differential gene expression analyses on the individuals stratified according to tumor <italic toggle="yes">DUX4</italic> expression status. Gene Ontology (GO) network analyses on the upregulated genes in <italic toggle="yes">DUX4</italic>-positive cancers identified multiple clusters of development-associated terms, consistent with the known role of <italic toggle="yes">DUX4</italic> in early embryogenesis (<xref rid="SD1" ref-type="supplementary-material">Fig. S2A</xref>; <xref rid="R18" ref-type="bibr">de Iaco et al., 2017</xref>; <xref rid="R37" ref-type="bibr">Hendrickson et al., 2017</xref>; <xref rid="R111" ref-type="bibr">Sugie et al., 2020</xref>; <xref rid="R118" ref-type="bibr">Whiddon et al., 2017</xref>). By contrast, we found a single network associated with downregulated genes: GO terms corresponding to humoral or cell-mediated immunity (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). Using an IFN-&#947; gene signature predictive of response to blockade of the PD-1/PD-L1 axis, we found that <italic toggle="yes">DUX4-</italic>expressing cancers have statistically lower levels of IFN-&#947; activity (<xref rid="SD1" ref-type="supplementary-material">Fig. S2B</xref>; <xref rid="R5" ref-type="bibr">Ayers et al., 2017</xref>). Consistent with IFN-&#947; suppression, we observed extensive downregulation of genes involved in anti-tumor immunity such as those involved in MHC class I-dependent antigen presentation and T cell activation, checkpoint proteins, and chemokines involved in effector T cell recruitment. <italic toggle="yes">DUX4</italic>-expression was also correlated with suppression of genes critical for MHC class II-mediated antigen presentation, namely: MHC class II isotypes (<italic toggle="yes">HLA&#8211;DP/DQ/DR)</italic>, <italic toggle="yes">HLA-DM</italic> and <italic toggle="yes">HLA-DO</italic>, and the invariant chain (<italic toggle="yes">CD74</italic>) (<xref rid="R92" ref-type="bibr">Roche &amp; Furuta, 2015</xref>). MHC class II gene expression is regulated by the transactivator CIITA via a conserved SXY-module present in the promoter regions of these genes. <italic toggle="yes">CIITA</italic> is induced by IFN-&#947; and is also conspicuously downregulated in <italic toggle="yes">DUX4</italic>-expressing tumors (<xref rid="F2" ref-type="fig">Fig. 2B</xref>; (<xref rid="R28" ref-type="bibr">Glimcher &amp; Kara, 1992</xref>; <xref rid="R72" ref-type="bibr">Masternak et al., 2000</xref>; <xref rid="R105" ref-type="bibr">Steimle et al., 1993</xref>, <xref rid="R106" ref-type="bibr">1994</xref>). MHC class II-mediated antigen presentation can regulate T cell abundance in the tumor microenvironment and patient response to PD-1 blockade (<xref rid="R50" ref-type="bibr">Johnson et al., 2020</xref>). These analyses suggest that <italic toggle="yes">DUX4</italic> expression in the metastatic context induces an immunosuppressive gene expression program, concordant with its established function in inhibiting JAK-STAT signaling in primary cancers (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>).</p><p id="P17">We hypothesized that <italic toggle="yes">DUX4</italic> expression in these cancers will generate related transcriptomic signals consistent with CD8<sup>+</sup> T cell exclusion from the tumor. We assessed this using an effector CD8<sup>+</sup> T cell transcriptomic signature developed from initial studies of the IMvigor210 phase 2 trial (<xref rid="R6" ref-type="bibr">Balar et al., 2017</xref>; <xref rid="R93" ref-type="bibr">Rosenberg et al., 2016</xref>). <italic toggle="yes">DUX4</italic>-expressing cancers had lower measures of the gene signature, consistent with decreased CD8<sup>+</sup> T cell infiltration into the tumor (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). We also investigated the possible effects of <italic toggle="yes">DUX4</italic> expression on the exclusion of other immune cell types using gene signatures developed from The Cancer Genome Atlas (<xref rid="R16" ref-type="bibr">Danaher et al., 2017</xref>). In these analyses, we recapitulated the observation of lower CD8<sup>+</sup> T cell signature associated with <italic toggle="yes">DUX4</italic> positivity (<xref rid="SD1" ref-type="supplementary-material">Fig. S2C</xref>). In addition, we observed patterns consistent with widespread immune cell exclusion from the tumor microenvironment (<xref rid="SD1" ref-type="supplementary-material">Fig. S2D</xref>).</p><p id="P18">Defects in chemokine signaling could partially account for the observed <italic toggle="yes">DUX4-</italic>associated decrease in immune gene signature measurements. To test this hypothesis, we examined expression of chemokines involved in immune cell recruitment. In <italic toggle="yes">DUX4</italic>-expressing cancers, we observed lower mRNA levels of <italic toggle="yes">CXCL9</italic> and <italic toggle="yes">CXCL10</italic>, chemokines which recruit T cells to the tumor site (<xref rid="F2" ref-type="fig">Fig. 2D</xref>&#8211;<xref rid="F2" ref-type="fig">E</xref>; <xref rid="R79" ref-type="bibr">Nagarsheth et al., 2017</xref>). Utilizing a chemokine signature associated with host immune response to solid tumors, we observed that <italic toggle="yes">DUX4</italic> expression was correlated with broad reduction in the expression of chemokine signaling genes, beyond T cell-associated signals (<xref rid="SD1" ref-type="supplementary-material">Fig. S2E</xref>; <xref rid="R15" ref-type="bibr">Coppola et al., 2011</xref>).</p><p id="P19">We directly assessed the correlation of <italic toggle="yes">DUX4</italic> expression to immune cell exclusion by examining CD8<sup>+</sup> T cell abundance in the tumor microenvironment, measured by immunohistochemistry (IHC) on formalin fixed paraffin embedded (FFPE) patient tumor sections. We verified that <italic toggle="yes">DUX4</italic> expression in the advanced urothelial carcinoma tumors was associated with an immune exclusion phenotype: a higher proportion of <italic toggle="yes">DUX4</italic>+ tumors exhibit either an immune-excluded or immune-desert phenotype compared to malignancies where <italic toggle="yes">DUX4</italic> is silent (<xref rid="F2" ref-type="fig">Fig. 2F</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S2F</xref>). We similarly examined the correlation of <italic toggle="yes">DUX4</italic> expression status with PD-L1 levels in the tumor and immune compartments quantified via IHC. We determined that <italic toggle="yes">DUX4</italic> expression was associated with a significant decrease in PD-L1 levels on both tumor and host immune cells, consistent with <italic toggle="yes">DUX4</italic>-induced suppression of IFN-&#947; signaling (<xref rid="F2" ref-type="fig">Fig. 2G</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S2G</xref>, <xref rid="F2" ref-type="fig">Fig. 2H</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S2H</xref>). PD-L1 expression on immune cells such as dendritic cells and macrophages modulate anti-tumor immune suppression and response to ICI in <italic toggle="yes">in vivo</italic> mouse models (<xref rid="R60" ref-type="bibr">Lau et al., 2017</xref>; <xref rid="R66" ref-type="bibr">Lin et al., 2018</xref>; <xref rid="R82" ref-type="bibr">Noguchi et al., 2017</xref>). Importantly, PD-L1 levels on immune cells are correlated with response to ICI in clinical trials (<xref rid="R85" ref-type="bibr">Powles et al., 2014</xref>; <xref rid="R93" ref-type="bibr">Rosenberg et al., 2016</xref>).</p></sec><sec id="S5"><title>DUX4 expression is correlated with poor response to immune checkpoint inhibition in advanced urothelial carcinoma</title><p id="P20">Given the correlation between cancer <italic toggle="yes">DUX4</italic> expression and signatures of anti-tumor immune response suppression, we sought to understand if <italic toggle="yes">DUX4</italic> expression in patient tumors was associated with accompanying changes to overall survival during PD-L1 inhibition. <italic toggle="yes">DUX4</italic> expression was associated with a significant decrease in objective response rates, assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). As expected, higher tumor mutational burden (TMB) was linked to improved survival outcomes in this cohort (<xref rid="F3" ref-type="fig">Fig. 3B</xref>). Interestingly, we found that <italic toggle="yes">DUX4</italic> expression was correlated with statistically lower survival rates in this cohort after crudely adjusting for the effects of TMB by removing the bottom quartile of patients, those with the lowest number of missense mutations in their tumors (<xref rid="F3" ref-type="fig">Fig. 3C</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S3A</xref>). Those results motivated us to more carefully control for the effects of other patient covariates in order to better clarify the effects of <italic toggle="yes">DUX4</italic> expression on survival.</p></sec><sec id="S6"><title>Risk assignments are improved with <italic toggle="yes">DUX4</italic> expression</title><p id="P21">We next determined whether <italic toggle="yes">DUX4</italic> expression was a significant predictor of survival for ICI-treated patients after controlling for TMB and other potentially relevant variables in a statistically rigorous manner. We used Cox Proportional Hazards (PH) regression to quantify the effects of multiple clinical, demographic, and molecular features on risk of death during ICI. For these and subsequent analyses, we elected to define <italic toggle="yes">DUX4</italic>-negative samples as those with <italic toggle="yes">DUX4</italic> expression levels &lt; 0.25 TPM. This scheme excludes 126 patients but presumably produces more reliable categorizations, avoiding potential misclassifications due to loss of sensitivity of bulk RNA-Seq at very low expression levels (<xref rid="R77" ref-type="bibr">Mortazavi et al., 2008</xref>). In the context of multivariate Cox PH regression, which controls for the confounding effects of all other covariates simultaneously, we observed that TMB was positively associated with survival [hazard ratio (HR) = 0.14], as expected. Conversely, <italic toggle="yes">DUX4</italic> expression, Eastern Cooperative Oncology Group Performance Status (ECOG PS) &gt; 0, and previous administration of platinum chemotherapy were correlated with increased risk (or shorter survival), while other features that have previously been reported as associated with reduced survival [e.g., <italic toggle="yes">TGFB1</italic> expression (<xref rid="R71" ref-type="bibr">Mariathasan et al., 2018</xref>)] did not remain significant after controlling for TMB and other variables. In particular, <italic toggle="yes">DUX4</italic> positivity was associated with dramatically worse survival, with a 3.2-fold increase in risk of death at any point in time compared to <italic toggle="yes">DUX4</italic>-negative status (<xref rid="F4" ref-type="fig">Fig. 4A</xref>, Table 1, <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>).</p><p id="P22">We next investigated if <italic toggle="yes">DUX4</italic> expression status carried added value as a predictor over routinely collected clinical and molecular information. We focused on the variables with significant hazard ratios under both the univariate and multivariate regression settings: <italic toggle="yes">DUX4</italic> expression status, TMB, ECOG PS, and history of platinum chemotherapy. We employed goodness of fit measurements, which compare the observed data to expectations from Cox PH models created using various combinations of the covariates. In these analyses, we observed a quantifiable improvement in data-model congruence with the addition of <italic toggle="yes">DUX4</italic> expression status (<xref rid="F4" ref-type="fig">Fig. 4B</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S4A</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">B</xref>). Additionally, we measured statistically significant differences in the likelihoods of the reduced models (without <italic toggle="yes">DUX4</italic> expression as a predictor) when compared to the full model (employs all covariates) (Table 2). Taken together, these analyses indicate that <italic toggle="yes">DUX4</italic> expression status is an informative predictor of risk under ICI treatment.</p><p id="P23">We evaluated the utility of <italic toggle="yes">DUX4</italic> expression status for pre-treatment risk assignment in predicting patient response to ICI. We trained full and reduced Cox PH models on randomly sampled patients (training set, 70% of the cohort) and quantified their respective risk scores. A reference risk score per model was computed as the median score across the training set and was used to ascribe patients into low- vs. high-risk groups. Using these models, we quantified risk scores on the individuals excluded from model construction (test set, 30% of the patients), and similarly assigned patients into low- or high-risk groups based on the training set reference score. By empirically quantifying survival of the two risk groups using KM (Kaplan-Meier) estimation, we found that the full model stratifies patients in an informative manner, appropriately discriminating patients with longer vs. shorter survival times (<xref rid="F4" ref-type="fig">Fig. 4C</xref>, <xref rid="SD1" ref-type="supplementary-material">Fig. S4C</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">D</xref>). Further, the addition of <italic toggle="yes">DUX4</italic> expression status improves model performance as illustrated by the time-dependent Brier score, a measure of survival prediction accuracy at specific timepoints (<xref rid="SD1" ref-type="supplementary-material">Fig. S4E</xref>).</p></sec><sec id="S7"><title><italic toggle="yes">DUX4</italic> expression impedes response to ICI after controlling for other clinical characteristics</title><p id="P24">We used a Random Survival Forest (RSF) model to quantify the effect of <italic toggle="yes">DUX4</italic> expression on survival in ICI-treated advanced urothelial carcinoma patients (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>). The Random Survival Forest (RSF) is a machine learning ensemble, an extension of the Random Forest algorithm for right-censored data (<xref rid="R10" ref-type="bibr">Breiman, 2001</xref>). It can provide accurate estimates of risk and survival probability at definite times by aggregating predictions from a multitude of base learners (survival trees) (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>). RSFs have been successfully used to study time-to-event problems in medicine, including measurement of variable importance (<xref rid="R20" ref-type="bibr">Dietrich et al., 2016</xref>; <xref rid="R39" ref-type="bibr">Hsich et al., 2019</xref>; <xref rid="R41" ref-type="bibr">Ishwaran et al., 2009</xref>; <xref rid="R83" ref-type="bibr">O&#8217;Brien et al., 2021</xref>; <xref rid="R98" ref-type="bibr">Semeraro et al., 2011</xref>). We utilized the RSF model to address potential limitations of our Cox PH analyses. First, the RSF model is fully non-parametric and as such does not operate under the Cox PH assumptions: a constant relative hazard between strata over time (proportional hazards), a linear relationship between the predictors and the log hazard, and the unspecified baseline hazard function. Second, the RSF model can compute estimates of absolute risk and survival probability over time independent of a reference, unlike relative risk models such as Cox PH (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>).</p><p id="P25">We used all available molecular, clinical, and demographic covariates to grow an RSF. We randomly selected 70% of the patients to grow the forest, with the resulting model having an Out-of-Bag (OOB) error of 38.4%. The OOB error stabilizes with increasing number of trees and converges to the leave-one-out cross-validation error estimate. Thus, OOB error is characterized as an unbiased estimate of the model&#8217;s true prediction error (<xref rid="R10" ref-type="bibr">Breiman, 2001</xref>; <xref rid="R34" ref-type="bibr">Hastie et al., 2009</xref>). In some instances, the OOB error provides overestimates and some reports have recommended treating it as an upper bound (<xref rid="R11" ref-type="bibr">Bylander, 2002</xref>; <xref rid="R47" ref-type="bibr">Janitza &amp; Hornung, 2018</xref>; <xref rid="R75" ref-type="bibr">Mitchell, 2011</xref>). Thus, we measured the RSF model&#8217;s test error using a holdout set (the remaining 30% of the cohort) excluded from training. The RSF model recorded a test error of 32.6% illustrating an appropriate fit (<xref rid="SD1" ref-type="supplementary-material">Fig. S5A</xref>). Our error measurements are comparable to <xref rid="R42" ref-type="bibr">Ishwaran, et al. (2008)</xref>, suggesting our model can be used for inference purposes. Further, the time-dependent Brier score of the RSF model on the training and test sets confirms informative survival prediction (<xref rid="SD1" ref-type="supplementary-material">Fig. S5B</xref>).</p><p id="P26">The RSF model predicted worse survival outcomes in patients with <italic toggle="yes">DUX4</italic>-expressing cancers compared to their <italic toggle="yes">DUX4</italic>-silent counterparts. These predictions were mirrored in the test dataset, illustrating robustness of the model (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). Using time-dependent Receiver Operating Characteristic (ROC) curve analyses, we identified the time range for which the RSF predictive performance is statistically divergent from random guessing: approximately 6 to 20 months (<xref rid="SD1" ref-type="supplementary-material">Fig. S5C</xref>). In this window we observed significant survival differences between patients with <italic toggle="yes">DUX4</italic>+ and <italic toggle="yes">DUX4</italic>&#8722; tumors. We highlighted the model&#8217;s performance at predicting 1-year and 1.5-year survival, typical timepoints of clinical interest. For these times, the RSF appropriately discriminates patient death and survival (<xref rid="SD1" ref-type="supplementary-material">Fig. S5D</xref>). Examining the absolute effects of <italic toggle="yes">DUX4</italic> expression on survival, the RSF model predicted an approximately 20% decrease in both 1-year and 1.5-year survival probabilities in patients with <italic toggle="yes">DUX4</italic>-expressing cancers (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). Importantly, RSF survival predictions conform closely with the empirical survival estimates obtained via the Kaplan-Meier model (<xref rid="F5" ref-type="fig">Fig. 5C</xref>).</p><p id="P27">We sought to determine the importance of <italic toggle="yes">DUX4</italic> expression status relative to the other covariates in the RSF model. We measured feature importance using estimated Shapley values, which quantify the marginal contribution of each variable to the RSF prediction (<xref rid="R69" ref-type="bibr">Lundberg &amp; Lee, 2017</xref>; <xref rid="R70" ref-type="bibr">Maksymiuk et al., 2020</xref>; <xref rid="R99" ref-type="bibr">Shapley, 1953</xref>; <xref rid="R108" ref-type="bibr">&#352;trumbelj &amp; Kononenko, 2014</xref>). Specifically, Shapley values measure variable contributions to predictions at the level of each patient. Contributions to the overall performance of the RSF model can be assessed by examining the aggregated summary: the average of the absolute Shapley values for a predictor across the patient cohort. We estimated Shapley values associated with predicting ensemble mortality, the RSF risk estimate. In these analyses, ECOG PS had the largest contribution, followed by TMB and <italic toggle="yes">DUX4</italic> expression (<xref rid="SD1" ref-type="supplementary-material">Fig. S5E</xref>). We validated these feature rankings using two independent metrics. The first metric was permutation importance, which quantifies the change in prediction error associated with permutation of a variable&#8217;s data; important covariates will record large deviations from the original predictions (<xref rid="R10" ref-type="bibr">Breiman, 2001</xref>; <xref rid="R40" ref-type="bibr">Ishwaran, 2007</xref>). The second measure employed was minimal depth, a measure of the variable-node-to-root-node distance within the survival trees of the RSF; important variables tend to have smaller minimal depth values as they are typically used for earlier decision splits (<xref rid="R44" ref-type="bibr">Ishwaran et al., 2010</xref>, <xref rid="R43" ref-type="bibr">2011</xref>). Feature contributions measured using permutation importance and minimal depth were consistent with the Shapley-based assignments, notably identifying <italic toggle="yes">DUX4</italic> expression as an important contributor to patient survival outcomes (<xref rid="SD1" ref-type="supplementary-material">Fig. S5E</xref>). We investigated time-dependent changes in variable importance by estimating Shapley values associated with predicting survival probability at distinct time points along the observation window. Interestingly, we observed the strong dependence on ECOG PS for predicting survival at early timepoints under this paradigm. The importance of <italic toggle="yes">DUX4</italic> expression for survival prediction is most prominent at later times (<xref rid="F5" ref-type="fig">Fig. 5D</xref>). Altogether, we found that diverse variable importance measures converge on identifying <italic toggle="yes">DUX4</italic> as a major contributor to patient survival prediction.</p><p id="P28">We sought to quantify the effect of <italic toggle="yes">DUX4</italic> expression on survival predictions after controlling for the effects of the other covariates. With Shapley dependence plots, which allows visualization of the marginal effects of a variable on the predicted outcome, we measured the expected negative correlation between TMB and mortality (<xref rid="SD1" ref-type="supplementary-material">Fig. S5F</xref>; <xref rid="R68" ref-type="bibr">Lundberg et al., 2020</xref>). We performed a similar dependence analysis on <italic toggle="yes">DUX4</italic> expression and observed a clear separation of positive and negative Shapley values based on <italic toggle="yes">DUX4</italic>-positive and -negative status, respectively. These results signify an increase in predicted risk of death associated with <italic toggle="yes">DUX4</italic> expression (<xref rid="SD1" ref-type="supplementary-material">Fig. S5G</xref>). Shapley values are scaled, variable attributions which add up to the difference between the prediction for an individual and the average prediction across the entire cohort and thus require transformation to get absolute measures of risk. To quantify the effects of TMB and <italic toggle="yes">DUX4</italic> expression in the appropriate risk units (mortality, expected number of deaths), we utilized partial dependence as an alternative way to represent mortality predictions as a function of these variables, marginalized over the other predictors in the data (<xref rid="R25" ref-type="bibr">Friedman, 2001</xref>). Specifically, the average model predictions across the individuals in the cohort are calculated over the unique predictor values. The marginal effects of TMB and <italic toggle="yes">DUX4</italic> expression measured via partial and Shapley dependence analyses show strong concordance. Comparison of the patients with the lowest versus highest TMB revealed an approximately 67% difference in mortality. On the other hand, we measured an approximately 53% increase in mortality associated with <italic toggle="yes">DUX4</italic>-positivity (<xref rid="SD1" ref-type="supplementary-material">Fig. S5H</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">I</xref>). We then extended the partial dependence analyses to survival probability predictions over time. In this paradigm, we similarly observed that higher TMB was correlated with increased survival probability, more pronounced at later times (<xref rid="F5" ref-type="fig">Fig. 5E</xref>). <italic toggle="yes">DUX4</italic> expression was correlated with poorer survival outcomes, with a 1-year and 1.5-year survival difference of 20.7% and 19.2% between patients with <italic toggle="yes">DUX4</italic>+ and <italic toggle="yes">DUX4</italic>&#8722; tumors, respectively. Strikingly, our analyses measure a difference of at least 12.5 months in median survival between the <italic toggle="yes">DUX4</italic>+ and <italic toggle="yes">DUX4</italic>&#8722; strata (<xref rid="F5" ref-type="fig">Fig. 5F</xref>). Overall, our analyses demonstrate a significant and robust decrease in survival attributable to <italic toggle="yes">DUX4</italic> expression in advanced cancers.</p></sec></sec><sec id="S8"><title>DISCUSSION</title><p id="P29"><italic toggle="yes">DUX4</italic> expression is a common feature of metastasis and may be an important driver of immune evasion. While the mechanism governing <italic toggle="yes">DUX4</italic> de-repression in cancer remains to be elucidated, we show that <italic toggle="yes">DUX4</italic> expression in the metastatic context is associated with reduced anti-tumor immunity, mirroring previous observations in primary cancers and cancer cell line models (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>), and is correlated with decreased patient survival under ICI treatment.</p><p id="P30">The prognostic value of IFN-&#947; activity (<xref rid="R5" ref-type="bibr">Ayers et al., 2017</xref>; <xref rid="R32" ref-type="bibr">Grasso et al., 2020</xref>; <xref rid="R80" ref-type="bibr">Newell et al., 2022</xref>) and its non-redundancy relative to TMB in terms of influencing ICI response is widely appreciated (Cristescu et al., 2018; <xref rid="R80" ref-type="bibr">Newell et al., 2022</xref>; <xref rid="R94" ref-type="bibr">Rozeman et al., 2021</xref>). For example, patients with advanced melanoma that is nonresponsive to anti-CTLA-4 or anti-PD-1/PD-L1 therapy have higher frequencies of genetic alterations associated with IFN-&#947; signaling defects compared to responsive patients (<xref rid="R26" ref-type="bibr">Gao et al., 2016</xref>; <xref rid="R81" ref-type="bibr">Nguyen et al., 2021</xref>; <xref rid="R109" ref-type="bibr">Sucker et al., 2017</xref>). DUX4 has been implicated in modifying IFN-&#947; activity through direct binding and inhibition of STAT1 via its C-terminal domain (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>; <xref rid="R103" ref-type="bibr">Spens et al., 2023</xref>). Our sequence analyses show that <italic toggle="yes">DUX4</italic> transcripts in the metastatic context contain the full-length coding region, suggestive of an intact capability as a STAT1 suppressor. <italic toggle="yes">DUX4</italic>&#8217;s ubiquitous expression across metastatic cancers and our controlled survival analyses emphasize <italic toggle="yes">DUX4</italic> as an underappreciated contributor to ICI resistance.</p><p id="P31">Our RSF model allowed us to interrogate changes in variable importance over time. For instance, the contribution of <italic toggle="yes">DUX4</italic> expression to survival prediction is most prominent at later time points, suggesting principal effects on long-term survival. Intriguingly, these analyses revealed the outsize influence of ECOG PS, a measure of patient functional status, on survival at early timepoints relative to other patient covariates. ECOG PS negatively impacts patient survival during ICI therapy, inferred from our multivariate Cox PH analysis and from findings of the IMvigor210 clinical trial: patients with ECOG PS = 2 (n = 24) had a median overall survival of 8.1 months, lower than the subgroup with ECOG PS &lt; 2 (n = 35) whose median survival was not reached during the observation period (<xref rid="R6" ref-type="bibr">Balar et al., 2017</xref>). Other studies have similarly reported poorer outcomes associated with ICI treatment in patients with high ECOG PS (<xref rid="R12" ref-type="bibr">Chalker et al., 2022</xref>; <xref rid="R56" ref-type="bibr">Krishnan et al., 2022</xref>; Petrillo et al., 2020; <xref rid="R97" ref-type="bibr">Sehgal et al., 2021</xref>). Altogether, these results possibly indicate the existence of co-occurring conditions in patients with higher degrees of disability, predisposing them to adverse effects associated with ICI treatment&#8212; comorbidities whose effects presumably manifest shortly after therapy commencement. Our data underscore the utility of time-dependent approaches in identifying covariate-linked survival effects which may not be apparent in a summary computed over the entire time period.</p><p id="P32">Our results may have broad implications for ICI treatment. First, <italic toggle="yes">DUX4</italic> expression may promote patient resistance in a wide array of ICI modalities. Our previous work showed that <italic toggle="yes">DUX4</italic> expression is associated with resistance to anti-CTLA-4 and anti-PD-1 therapies (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>). In our current study, we comprehensively demonstrate that <italic toggle="yes">DUX4</italic> modulates patient response to PD-L1 blockade. We also report that <italic toggle="yes">DUX4</italic> expression in metastasis is correlated with downregulation of <italic toggle="yes">TIGIT</italic> (<xref rid="R127" ref-type="bibr">Zhang et al., 2018</xref>) and other immune checkpoints whose interception are currently under clinical investigation: <italic toggle="yes">HAVCR2/TIM3</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02608268" ext-link-type="uri">NCT02608268</ext-link>; <xref rid="R21" ref-type="bibr">Dixon et al., 2021</xref>) and <italic toggle="yes">LAG3</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02658981" ext-link-type="uri">NCT02658981</ext-link>; <xref rid="R2" ref-type="bibr">Amaria et al., 2022</xref>; <xref rid="R113" ref-type="bibr">Tawbi et al., 2022</xref>). Second, the pervasive expression of <italic toggle="yes">DUX4</italic> in all the metastatic cohorts we examined exhibits its potential as a pan-cancer biomarker. We show that binary categorization of patients according to <italic toggle="yes">DUX4</italic> expression status was sufficient to stratify patients according to ICI response. Screening for <italic toggle="yes">DUX4</italic> tumor expression, with binarized results such as through IHC using anti-DUX4 antibodies, could have clinical utility.</p><p id="P33">Our data motivate the investigation into <italic toggle="yes">DUX4&#8217;s</italic> potential to prognosticate response to ICI. However, our current study is limited by the availability of sufficiently-sized ICI-treated cohorts with associated patient data on relevant characteristics such as demographics and risk factors. Additional randomized trial data from diverse metastatic cancer cohorts, with adequate genomic and clinical data, is imperative. As these become available in the future, extending the analyses we have outlined in this study will be important to appraise <italic toggle="yes">DUX4</italic>&#8217;s definitive clinical relevance, contextualized amongst response-modifying clinical variables, in the use of immunotherapy in the treatment of metastatic cancer.</p></sec><sec id="S9"><title>METHODS</title><sec id="S10"><title>Genome annotations, gene expression, and Gene Ontology (GO) enrichment analyses</title><p id="P34">A genome annotation was created through merging of the UCSC knownGene (<xref rid="R74" ref-type="bibr">Meyer et al., 2013</xref>), Ensembl 71 (<xref rid="R24" ref-type="bibr">Flicek et al., 2013</xref>), and MISO v2.0 (<xref rid="R53" ref-type="bibr">Katz et al., 2010</xref>) annotations for the hg19/GRCh37 assembly. Further, this annotation was expanded by generating all possible combinations of annotated 5&#8217; and 3&#8217; splice sites within each gene. RNA-seq reads were mapped to the transcriptome using RSEM v1.2.4 (<xref rid="R62" ref-type="bibr">B. Li &amp; Dewey, 2011</xref>) calling Bowtie v1.0.0 (<xref rid="R58" ref-type="bibr">Langmead et al., 2009</xref>), with the option &#8220;-v 2.&#8221; TopHat v.2.0.8b (<xref rid="R117" ref-type="bibr">Trapnell et al., 2009</xref>) was used to map the unaligned reads to the genome and to the database of splice junctions obtained from the annotation merging described previously. Gene expression estimates (TPM, transcripts per million) obtained were normalized using the trimmed mean of M values (TMM) method (<xref rid="R91" ref-type="bibr">M. D. Robinson &amp; Oshlack, 2010</xref>). Endogenous expression of <italic toggle="yes">DUX4</italic> during early embryogenesis range from approximately 2 to 10 TPM (<xref rid="R13" ref-type="bibr">Chew et al., 2019</xref>; <xref rid="R37" ref-type="bibr">Hendrickson et al., 2017</xref>). We have therefore defined DUX4-positive samples as those with expression levels &gt; 1 TPM. In the differential gene expression analyses for the DUX4-positive vs. -negative comparison, gene expression values per sample group were compared using a two-sided Mann-Whitney <italic toggle="yes">U</italic> test. Differentially expressed genes illustrated in <xref rid="F2" ref-type="fig">Figure 2B</xref> were identified as those with an absolute log<sub>2</sub>(fold-change) &#8805; log<sub>2</sub>(1.25) and a <italic toggle="yes">p</italic>-value &lt; 0.05. GO enrichment analyses, using the clusterProfiler package (<xref rid="R122" ref-type="bibr">Wu et al., 2021</xref>; <xref rid="R126" ref-type="bibr">Yu et al., 2012</xref>), were performed on <italic toggle="yes">DUX4</italic>-upregulated or -downregulated genes [absolute log<sub>2</sub>(fold-change) &#8805; log<sub>2</sub>(1.5) and a <italic toggle="yes">p</italic>-value &lt; 0.05] compared against the set of coding genes. Significant GO terms were defined as &#8220;Biological Process&#8221; terms with a Benjamini-Hochberg FDR-adjusted <italic toggle="yes">p</italic>-value &lt; 0.05. The top 25 significant GO terms were illustrated (<xref rid="F2" ref-type="fig">Fig. 2A</xref> and <xref rid="SD1" ref-type="supplementary-material">Fig. S2A</xref>). To investigate <italic toggle="yes">DUX4</italic> RNA-seq coverage patterns, a fasta file containing the <italic toggle="yes">DUX4</italic> cDNA sequence was assembled, indexed using samtools (<xref rid="R63" ref-type="bibr">H. Li et al., 2009</xref>), and used as a reference for read pseudoalignment by kallisto v.0.46.1 (<xref rid="R9" ref-type="bibr">Bray et al., 2016</xref>). The following kallisto parameters were used: kmer size of 31, estimated fragment length of 200, and estimated fragment length standard deviation of 80. Usage of the single-end option (&#8220;--single&#8221;) and bias correction (&#8220;--bias&#8221;) were also specified. <italic toggle="yes">DUX4</italic> read coverage was visualized using the Integrative Genomics Viewer (IGV, <xref rid="R116" ref-type="bibr">Thorvaldsd&#243;ttir et al., 2013</xref>).</p></sec><sec id="S11"><title>Gene signature analyses</title><p id="P35">For a given gene set, z-score normalization of the expression values per gene was performed across the patient cohort. The signature score was defined as the mean of the normalized values across the genes of the set.</p></sec><sec id="S12"><title>Survival analyses, goodness of fit measures, and risk modeling</title><p id="P36">Kaplan-Meier (KM) estimation, <italic toggle="yes">p</italic>-value estimates from the log-rank test, and Cox Proportional Hazards (PH) regression in the univariate and multivariate contexts were performed using the survival package (<xref rid="R114" ref-type="bibr">T. Therneau, 2022</xref>; <xref rid="R115" ref-type="bibr">T. M. Therneau &amp; Grambsch, 2000</xref>). Goodness of fit evaluations of the Cox PH models were done by measuring the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). AIC and BIC metrics balance model complexity with maximized likelihood, penalizing feature number increases without a concomitant improvement in performance. The likelihood ratio test was also used to compare goodness of fit of full (all variables) vs. reduced (subset of variables) Cox PH models. Specifically, the null hypothesis that the simple model provides as good as a fit as the more complex model was evaluated. The AIC, BIC, and likelihood ratio test <italic toggle="yes">p</italic>-values were computed using R&#8217;s stats package (<xref rid="R88" ref-type="bibr">R Core Team, 2022</xref>). For the Cox PH risk modeling, the patients were randomly assigned into training (70%) and test (30%) datasets. The createDataPartition() function from the caret package (<xref rid="R57" ref-type="bibr">Kuhn, 2022</xref>) was used to preserve the <italic toggle="yes">DUX4</italic> status class distribution after splitting. Full and reduced Cox PH models were created using the training data and the risk scores for each respective model were calculated using caret&#8217;s predict.coxph() function. For a given patient, the calculated risk score is equal to the hazard ratio relative to a &#8220;reference patient&#8221; (an individual whose covariate values are set to the respective means, from the training set). Specifically, the risk score is the quotient of the patient&#8217;s and the reference&#8217;s exponentiated linear predictors (the sum of the covariates in the model, weighted by the model&#8217;s regression coefficients). A &#8220;reference risk score&#8221; for each model was defined as the median risk score in the training data. Patients were assigned into low- or high-risk groups if their risk scores were lower or higher than the reference, respectively. The trained models were used to calculate risk scores and assign risk labels (based on the training set risk score reference) in the test set. The survival difference between low- and high-risk patients were empirically assessed via KM estimation and the log-rank test. Visualizations were created using the ggplot2 (<xref rid="R119" ref-type="bibr">Wickham, 2016</xref>), dplyr (<xref rid="R120" ref-type="bibr">Wickham et al., 2022</xref>), and survminer (<xref rid="R52" ref-type="bibr">Kassambara et al., 2021</xref>) packages.</p></sec><sec id="S13"><title>Random Survival Forest, feature importance, and partial dependence</title><p id="P37">We implemented a Random Survival Forest (RSF) model, an ensemble of multiple base learners (survival trees), using the randomForestSRC package (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>). The RSF algorithm is an extension of the Random Forest Algorithm (<xref rid="R10" ref-type="bibr">Breiman, 2001</xref>) for usage with right-censored data. Here, B bootstrap datasets are created from the original data, used to grow B concomitant survival trees (usually constrained by membership size in the terminal nodes) constructed using a randomly selected subset of the variables. Terminal node statistics are obtained for each tree: the survival function (via the Kaplan-Meier estimator), the cumulative hazard function (CHF, via the Nelson-Aalen estimator), and mortality (expected number of deaths; sum of the CHF over time). The RSF prediction is the average across the forest. Of note, each bootstrap dataset excludes 36.8% of the original data on average, the out-of-bag (OOB) samples. Thus, predictions for a particular sample can be made using the subset of the trees for which it was excluded from training (OOB predictions). Similarly, the associated OOB error for the RSF model can calculated, representing an unbiased estimate of the test error. We randomly assigned patients into training (70%) and test (30%) datasets. Since the <italic toggle="yes">DUX4</italic>-positive status was a minority class, we utilized the createDataPartition() function from the caret package (<xref rid="R57" ref-type="bibr">Kuhn, 2022</xref>) to preserve the class distribution within the splits. To determine optimal hyperparameters, we evaluated 5,616 RSF models representing different combinations of ntree (number of trees), nodesize (minimum terminal node size), mtry (number of randomly selected splitting variables), na.action (handling of missing data), splitrule (splitting rule), and samptype (type of bootstrap). We selected the model with hyperparameters which minimized both the OOB training and the test errors (defined as 1 &#8211; concordance index), namely: ntree = 1500, nodesize = 15, mtry = 3, na.action = &#8220;na.impute&#8221;, splitrule = &#8220;bs.gradient&#8221;, and samptype = &#8220;swr.&#8221; We specified the use of an nsplit (number of random splits) value of 0 to indicate evaluation of all possible split points and usage of the optimum. For test set predictions, patients with missing data were omitted (na.action = &#8220;na.omit&#8221;).</p><p id="P38">Feature importance in the final RSF model was evaluated using 3 metrics. First, permutation importance was measured using randomForestSRC&#8217;s subsample() function. RSF permutation importance utilizes OOB values: a variable&#8217;s OOB data is permuted and the change in the new vs. original OOB prediction error is quantified. The RSF permutation importance values were standardized by dividing by the variance and multiplying by 100, and the variance and confidence regions were obtained via the delete-<italic toggle="yes">d</italic> jackknife estimator (<xref rid="R45" ref-type="bibr">Ishwaran &amp; Lu, 2019</xref>). Second, the tree-based feature importance metric minimal depth was calculated using randomForestSRC&#8217;s var.select() function. The minimal depth threshold (mean minimal depth) is the tree-averaged threshold (conservative = &#8220;medium&#8221;). Last, Shapley values were estimated using the fastshap package (<xref rid="R33" ref-type="bibr">Greenwell, 2021</xref>), using 1000 Monte Carlo repetitions. For each prediction, the sum of the estimated Shapley values was corrected (adjust = TRUE) to satisfy the efficiency (or local accuracy) property: for an individual <italic toggle="yes">i</italic>, the sum of <italic toggle="yes">i</italic>&#8217;s feature contributions equal the difference between the prediction for <italic toggle="yes">i</italic> and the average prediction across the entire cohort. For the overall measure of importance, the Shapley values were estimated from the mortality predictions from the RSF model (<xref rid="SD1" ref-type="supplementary-material">Fig S5E</xref>). Mortality is defined as the number of expected deaths over the observation window. That is, if all patients in the cohort shared the same covariate values as patient <italic toggle="yes">i</italic> who has mortality <italic toggle="yes">m</italic><sub><italic toggle="yes">i</italic></sub>, then an average of <italic toggle="yes">m</italic> deaths is expected (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>). For the time-dependent implementation, we estimated Shapley values associated with the per timepoint RSF survival probability predictions along the observation window (<xref rid="F5" ref-type="fig">Fig 5C</xref>).</p><p id="P39">The relationships of <italic toggle="yes">DUX4</italic> expression and TMB to mortality or survival probability (marginal contributions) were assessed via Shapley dependence plots and partial dependence plots. Partial dependence values were obtained using randomForestSRC&#8217;s partial() function and OOB predictions for mortality and survival probability were used as input. Visualizations were created in the R programming environment using the dplyr (<xref rid="R120" ref-type="bibr">Wickham et al., 2022</xref>), ggplot2 (<xref rid="R119" ref-type="bibr">Wickham, 2016</xref>), pammtools (<xref rid="R7" ref-type="bibr">Bender &amp; Scheipl, 2018</xref>), and plotly (<xref rid="R101" ref-type="bibr">Sievert, 2020</xref>) packages.</p></sec><sec id="S14"><title>Measuring survival model predictive accuracy</title><p id="P40">The time-dependent Receiver Operating Characteristic (ROC) curve analyses were done to evaluate the RSF model&#8217;s accuracy in differentiating patients who die before a particular time <italic toggle="yes">t</italic>, from those who survive past <italic toggle="yes">t</italic> (<xref rid="R35" ref-type="bibr">Heagerty &amp; Zheng, 2005</xref>). Specifically, for each timepoint, the cumulative/dynamic Area Under the ROC curve (AUC<sup>C/D</sup>) was calculated by computing the sensitivity (true positive rate) and specificity (1 &#8211; false positive rate) associated with using RSF-predicted mortality as the prognostic marker. The time-dependent AUC<sup>C/D</sup> and 95% confidence interval per time point were estimated using the timeROC package, which adds the inverse-probability-of-censoring weights (IPCW) to the sensitivity calculation to correct for selection bias due to right-censoring (<xref rid="R8" ref-type="bibr">Blanche et al., 2013</xref>). The out-of-bag (training) or the test mortality predictions were used as input. The time-dependent Brier score and the Continuous Ranked Probability Score (CRPS, integrated Brier score divided by time) for the Cox PH models were computed using the pec package (<xref rid="R76" ref-type="bibr">Mogensen et al., 2012</xref>). The time-dependent Brier score and the CRPS for the RSF model was calculated using the randomForestSRC package (<xref rid="R42" ref-type="bibr">Ishwaran et al., 2008</xref>). The Kaplan-Meier estimator for the censoring times was used to estimate the IPCW (cens.model = &#8220;marginal&#8221;). Harrell&#8217;s concordance index for the Cox PH and RSF models were calculated using the survival (<xref rid="R114" ref-type="bibr">T. Therneau, 2022</xref>; <xref rid="R115" ref-type="bibr">T. M. Therneau &amp; Grambsch, 2000</xref>) and randomForestSRC packages, respectively. Visualizations were created in the R programming environment using the dplyr (<xref rid="R120" ref-type="bibr">Wickham et al., 2022</xref>) and ggplot2 (<xref rid="R119" ref-type="bibr">Wickham, 2016</xref>) packages.</p></sec></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHPP2023.07.10.548412v2-supplement-1.pdf" id="d64e1476" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S15"><title>ACKNOWLEDGEMENTS</title><p id="P41">R.K.B. was supported in part by the NIH/NCI (R01 CA251138), NIH/NHLBI (R01 HL128239, R01 HL151651), and the Blood Cancer Discoveries Grant program through the Leukemia &amp; Lymphoma Society, Mark Foundation for Cancer Research, and Paul G. Allen Frontiers Group (8023-20). R.K.B is a Scholar of The Leukemia &amp; Lymphoma Society (1344-18) and holds the McIlwain Family Endowed Chair in Data Science. The results shown here are in part based upon data generated by the TCGA Research Network: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancergenome.nih.gov/" ext-link-type="uri">https://cancergenome.nih.gov/</ext-link>.</p><sec sec-type="COI-statement" id="S16"><title>COMPETING INTERESTS</title><p id="P42">R.K.B. is an inventor on a patent application submitted by Fred Hutchinson Cancer Center that covers DUX4 expression in cancers and response to immunotherapy. R.K.B. is a founder and scientific advisor of Codify Therapeutics and Synthesize Bio and holds equity in both companies. R.K.B. has received research funding from Codify Therapeutics unrelated to the current work. The remaining authors declare no competing interests.</p></sec></ack><ref-list><title>REFERENCES</title><ref id="R1"><mixed-citation publication-type="journal"><name name-style="western"><surname>Alspach</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lussier</surname><given-names>D. M.</given-names></name>, &amp; <name name-style="western"><surname>Schreiber</surname><given-names>R. D.</given-names></name> (<year>2019</year>). <article-title>Interferon &#947; and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity</article-title>. <source>Cold Spring Harbor Perspectives in Biology</source>, <volume>11</volume>(<issue>3</issue>). <pub-id pub-id-type="doi">10.1101/cshperspect.a028480</pub-id><pub-id pub-id-type="pmcid">PMC6396335</pub-id><pub-id pub-id-type="pmid">29661791</pub-id></mixed-citation></ref><ref id="R2"><mixed-citation publication-type="journal"><name name-style="western"><surname>Amaria</surname><given-names>R. N.</given-names></name>, <name name-style="western"><surname>Postow</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Burton</surname><given-names>E. M.</given-names></name>, <name name-style="western"><surname>Tezlaff</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>M. I.</given-names></name>, <name name-style="western"><surname>Torres-Cabala</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Glitza</surname><given-names>I. C.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Milton</surname><given-names>D. R.</given-names></name>, <name name-style="western"><surname>Busam</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Simpson</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>McQuade</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>M. K.</given-names></name>, <name name-style="western"><surname>Gershenwald</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Goepfert</surname><given-names>R. P.</given-names></name>, <name name-style="western"><surname>Keung</surname><given-names>E. Z.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>S. B.</given-names></name>, <name name-style="western"><surname>Betof-Warner</surname><given-names>A.</given-names></name>, &#8230; <name name-style="western"><surname>Tawbi</surname><given-names>H. A.</given-names></name> (<year>2022</year>). <article-title>Neoadjuvant relatlimab and nivolumab in resectable melanoma</article-title>. <source>Nature</source>, <volume>611</volume>(<issue>7934</issue>), <fpage>155</fpage>&#8211;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05368-8</pub-id><pub-id pub-id-type="pmid">36289334</pub-id><pub-id pub-id-type="pmcid">PMC9607737</pub-id></mixed-citation></ref><ref id="R3"><mixed-citation publication-type="journal"><name name-style="western"><surname>Antonescu</surname><given-names>C. R.</given-names></name>, <name name-style="western"><surname>Owosho</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Deniz</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Huryn</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>Y.-C.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S.-C.</given-names></name>, <name name-style="western"><surname>Singer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tap</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>I.-M.</given-names></name>, &amp; <name name-style="western"><surname>Fletcher</surname><given-names>C. D.</given-names></name> (<year>2017</year>). <article-title>Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases</article-title>. <source>The American Journal of Surgical Pathology</source>, <volume>41</volume>(<issue>7</issue>), <fpage>941</fpage>&#8211;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000000846</pub-id><pub-id pub-id-type="pmid">28346326</pub-id><pub-id pub-id-type="pmcid">PMC5468475</pub-id></mixed-citation></ref><ref id="R4"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ascierto</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Ferrucci</surname><given-names>P. F.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>del Vecchio</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Schmidt</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Schachter</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Queirolo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>G. v</given-names></name>, <name name-style="western"><surname>di Giacomo</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Svane</surname><given-names>I. M.</given-names></name>, <name name-style="western"><surname>Lotem</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bar-Sela</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Couture</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Mookerjee</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ghori</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>B. H.</given-names></name>, &amp; <name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name> (<year>2019</year>). <article-title>Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma</article-title>. <source>Nature Medicine</source>, <volume>25</volume>(<issue>6</issue>), <fpage>941</fpage>&#8211;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0448-9</pub-id><pub-id pub-id-type="pmid">31171878</pub-id></mixed-citation></ref><ref id="R5"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ayers</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lunceford</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Nebozhyn</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Loboda</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kaufman</surname><given-names>D. R.</given-names></name>, <name name-style="western"><surname>Albright</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>J. D.</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>S. P.</given-names></name>, <name name-style="western"><surname>Shankaran</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Piha-Paul</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Yearley</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Seiwert</surname><given-names>T. Y.</given-names></name>, <name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>McClanahan</surname><given-names>T. K.</given-names></name> (<year>2017</year>). <article-title>IFN-&#947;-related mRNA profile predicts clinical response to PD-1 blockade</article-title>. <source>The Journal of Clinical Investigation</source>, <volume>127</volume>(<issue>8</issue>), <fpage>2930</fpage>&#8211;<lpage>2940</lpage>. <pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id><pub-id pub-id-type="pmcid">PMC5531419</pub-id></mixed-citation></ref><ref id="R6"><mixed-citation publication-type="journal"><name name-style="western"><surname>Balar</surname><given-names>A. v</given-names></name>, <name name-style="western"><surname>Galsky</surname><given-names>M. D.</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Powles</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Petrylak</surname><given-names>D. P.</given-names></name>, <name name-style="western"><surname>Bellmunt</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Loriot</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Necchi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hoffman-Censits</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Perez-Gracia</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Dawson</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>van der Heijden</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Dreicer</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Srinivas</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Retz</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>R. W.</given-names></name>, <name name-style="western"><surname>Drakaki</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Vaishampayan</surname><given-names>U. N.</given-names></name>, <name name-style="western"><surname>Sridhar</surname><given-names>S. S.</given-names></name>, &#8230; <collab>IMvigor210 Study Group</collab>. (<year>2017</year>). <article-title>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial</article-title>. <source>Lancet (London, England)</source>, <volume>389</volume>(<issue>10064</issue>), <fpage>67</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32455-2</pub-id><pub-id pub-id-type="pmid">27939400</pub-id><pub-id pub-id-type="pmcid">PMC5568632</pub-id></mixed-citation></ref><ref id="R7"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>Scheipl</surname><given-names>F.</given-names></name> (<year>2018</year>). <article-title>pammtools: Piece-wise exponential Additive Mixed Modeling tools</article-title>. <source>ArXiv</source>. <pub-id pub-id-type="doi">10.48550/arXiv.1806.01042</pub-id></mixed-citation></ref><ref id="R8"><mixed-citation publication-type="journal"><name name-style="western"><surname>Blanche</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Dartigues</surname><given-names>J.-F.</given-names></name>, &amp; <name name-style="western"><surname>Jacqmin-Gadda</surname><given-names>H.</given-names></name> (<year>2013</year>). <article-title>Estimating and comparing timedependent areas under receiver operating characteristic curves for censored event times with competing risks</article-title>. <source>Statistics in Medicine</source>, <volume>32</volume>(<issue>30</issue>), <fpage>5381</fpage>&#8211;<lpage>5397</lpage>. <pub-id pub-id-type="doi">10.1002/sim.5958</pub-id><pub-id pub-id-type="pmid">24027076</pub-id></mixed-citation></ref><ref id="R9"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bray</surname><given-names>N. L.</given-names></name>, <name name-style="western"><surname>Pimentel</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Melsted</surname><given-names>P.</given-names></name>, &amp; <name name-style="western"><surname>Pachter</surname><given-names>L.</given-names></name> (<year>2016</year>). <article-title>Near-optimal probabilistic RNA-seq quantification</article-title>. <source>Nature Biotechnology</source>, <volume>34</volume>(<issue>5</issue>), <fpage>525</fpage>&#8211;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></mixed-citation></ref><ref id="R10"><mixed-citation publication-type="journal"><name name-style="western"><surname>Breiman</surname><given-names>L.</given-names></name> (<year>2001</year>). <article-title>Random Forests</article-title>. <source>Machine Learning</source>, <volume>45</volume>(<issue>1</issue>), <fpage>5</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1023/A:1010933404324</pub-id></mixed-citation></ref><ref id="R11"><mixed-citation publication-type="journal"><name name-style="western"><surname>Bylander</surname><given-names>T.</given-names></name> (<year>2002</year>). <article-title>Estimating Generalization Error on Two-Class Datasets Using Out-of-Bag Estimates</article-title>. <source>Machine Learning</source>, <volume>48</volume>(<issue>1/3</issue>), <fpage>287</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1023/A:1013964023376</pub-id></mixed-citation></ref><ref id="R12"><mixed-citation publication-type="journal"><name name-style="western"><surname>Chalker</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Voutsinas</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Q. V.</given-names></name>, <name name-style="western"><surname>Santana-Davila</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Baik</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Futran</surname><given-names>N. D.</given-names></name>, <name name-style="western"><surname>Houlton</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Laramore</surname><given-names>G. E.</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Parvathaneni</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Martins</surname><given-names>R. G.</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>K. D.</given-names></name>, &amp; <name name-style="western"><surname>Rodriguez</surname><given-names>C. P.</given-names></name> (<year>2022</year>). <article-title>Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients</article-title>. <source>Cancer Medicine</source>. <pub-id pub-id-type="doi">10.1002/cam4.4722</pub-id><pub-id pub-id-type="pmcid">PMC9678089</pub-id><pub-id pub-id-type="pmid">35349227</pub-id></mixed-citation></ref><ref id="R13"><mixed-citation publication-type="journal"><name name-style="western"><surname>Chew</surname><given-names>G.-L.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>A. E.</given-names></name>, <name name-style="western"><surname>De Neef</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sutliff</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Shadle</surname><given-names>S. C.</given-names></name>, <name name-style="western"><surname>Tapscott</surname><given-names>S. J.</given-names></name>, &amp; <name name-style="western"><surname>Bradley</surname><given-names>R. K.</given-names></name> (<year>2019</year>). <article-title>DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade</article-title>. <source>Developmental Cell</source>, <volume>50</volume>(<issue>5</issue>), <fpage>658</fpage>&#8211;<lpage>671.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2019.06.011</pub-id><pub-id pub-id-type="pmid">31327741</pub-id><pub-id pub-id-type="pmcid">PMC6736738</pub-id></mixed-citation></ref><ref id="R14"><mixed-citation publication-type="journal"><name name-style="western"><surname>Choi</surname><given-names>E.-Y. K.</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>D. G.</given-names></name>, <name name-style="western"><surname>McHugh</surname><given-names>J. B.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>R. M.</given-names></name>, <name name-style="western"><surname>Roulston</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Schuetze</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Chugh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Biermann</surname><given-names>J. S.</given-names></name>, &amp; <name name-style="western"><surname>Lucas</surname><given-names>D. R.</given-names></name> (<year>2013</year>). <article-title>Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology</article-title>. <source>The American Journal of Surgical Pathology</source>, <volume>37</volume>(<issue>9</issue>), <fpage>1379</fpage>&#8211;<lpage>1386</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0b013e318297a57d</pub-id><pub-id pub-id-type="pmid">23887164</pub-id></mixed-citation></ref><ref id="R15"><mixed-citation publication-type="journal"><name name-style="western"><surname>Coppola</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Nebozhyn</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Khalil</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yeatman</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Loboda</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>Mul&#233;</surname><given-names>J. J.</given-names></name> (<year>2011</year>). <article-title>Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling</article-title>. <source>The American Journal of Pathology</source>, <volume>179</volume>(<issue>1</issue>), <fpage>37</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.007</pub-id><pub-id pub-id-type="pmid">21703392</pub-id><pub-id pub-id-type="pmcid">PMC3123872</pub-id></mixed-citation></ref><ref id="R16"><mixed-citation publication-type="journal"><name name-style="western"><surname>Danaher</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dennis</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>D&#8217;Amico</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>White</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Disis</surname><given-names>M. L.</given-names></name>, <name name-style="western"><surname>Geller</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Odunsi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Beechem</surname><given-names>J.</given-names></name>, &amp; <name name-style="western"><surname>Fling</surname><given-names>S. P.</given-names></name> (<year>2017</year>). <article-title>Gene expression markers of Tumor Infiltrating Leukocytes</article-title>. <source>Journal for Immunotherapy of Cancer</source>, <volume>5</volume>, <fpage>18</fpage>. <pub-id pub-id-type="doi">10.1186/s40425-017-0215-8</pub-id><pub-id pub-id-type="pmid">28239471</pub-id><pub-id pub-id-type="pmcid">PMC5319024</pub-id></mixed-citation></ref><ref id="R17"><mixed-citation publication-type="journal"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name>, &amp; <name name-style="western"><surname>Chadwick</surname><given-names>B. P.</given-names></name> (<year>2016</year>). <article-title>Influence of Repressive Histone and DNA Methylation upon D4Z4 Transcription in Non-Myogenic Cells</article-title>. <source>PloS One</source>, <volume>11</volume>(<issue>7</issue>), <fpage>e0160022</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0160022</pub-id><pub-id pub-id-type="pmid">27467759</pub-id><pub-id pub-id-type="pmcid">PMC4965136</pub-id></mixed-citation></ref><ref id="R18"><mixed-citation publication-type="journal"><name name-style="western"><surname>de Iaco</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Planet</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Coluccio</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Verp</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Duc</surname><given-names>J.</given-names></name>, &amp; <name name-style="western"><surname>Trono</surname><given-names>D.</given-names></name> (<year>2017</year>). <article-title>DUX-family transcription factors regulate zygotic genome activation in placental mammals</article-title>. <source>Nature Genetics</source>, <volume>49</volume>(<issue>6</issue>), <fpage>941</fpage>&#8211;<lpage>945</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3858</pub-id><pub-id pub-id-type="pmid">28459456</pub-id><pub-id pub-id-type="pmcid">PMC5446900</pub-id></mixed-citation></ref><ref id="R19"><mixed-citation publication-type="journal"><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>E. S.</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>R. W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dries</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Chhabra</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Aref</surname><given-names>A. R.</given-names></name>, <name name-style="western"><surname>Ivanova</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Paweletz</surname><given-names>C. P.</given-names></name>, <name name-style="western"><surname>Bowden</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>C. W.</given-names></name>, <name name-style="western"><surname>Herter-Sprie</surname><given-names>G. S.</given-names></name>, <name name-style="western"><surname>Sorrentino</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Bisi</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Lizotte</surname><given-names>P. H.</given-names></name>, <name name-style="western"><surname>Merlino</surname><given-names>A. A.</given-names></name>, &#8230; <name name-style="western"><surname>Wong</surname><given-names>K.-K.</given-names></name> (<year>2018</year>). <article-title>CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation</article-title>. <source>Cancer Discovery</source>, <volume>8</volume>(<issue>2</issue>), <fpage>216</fpage>&#8211;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0915</pub-id><pub-id pub-id-type="pmid">29101163</pub-id><pub-id pub-id-type="pmcid">PMC5809273</pub-id></mixed-citation></ref><ref id="R20"><mixed-citation publication-type="journal"><name name-style="western"><surname>Dietrich</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Floegel</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Troll</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>K&#252;hn</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Rathmann</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sookthai</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>von Bergen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kaaks</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Adamski</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Prehn</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Boeing</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Schulze</surname><given-names>M. B.</given-names></name>, <name name-style="western"><surname>Illig</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Pischon</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kn&#252;ppel</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang-Sattler</surname><given-names>R.</given-names></name>, &amp; <name name-style="western"><surname>Drogan</surname><given-names>D.</given-names></name> (<year>2016</year>). <article-title>Random Survival Forest in practice: a method for modelling complex metabolomics data in time to event analysis</article-title>. <source>International Journal of Epidemiology</source>, <volume>45</volume>(<issue>5</issue>), <fpage>1406</fpage>&#8211;<lpage>1420</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyw145</pub-id><pub-id pub-id-type="pmid">27591264</pub-id></mixed-citation></ref><ref id="R21"><mixed-citation publication-type="journal"><name name-style="western"><surname>Dixon</surname><given-names>K. O.</given-names></name>, <name name-style="western"><surname>Tabaka</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Schramm</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Dionne</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Rozenblatt-Rosen</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Regev</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>Kuchroo</surname><given-names>V. K.</given-names></name> (<year>2021</year>). <article-title>TIM-3 restrains anti-tumour immunity by regulating inflammasome activation</article-title>. <source>Nature</source>, <volume>595</volume>(<issue>7865</issue>), <fpage>101</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03626-9</pub-id><pub-id pub-id-type="pmid">34108686</pub-id><pub-id pub-id-type="pmcid">PMC8627694</pub-id></mixed-citation></ref><ref id="R22"><mixed-citation publication-type="journal"><name name-style="western"><surname>Doki</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ajani</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wyrwicz</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Motoyama</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ogata</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kawakami</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>C.-H.</given-names></name>, <name name-style="western"><surname>Adenis</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>el Hajbi</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>di Bartolomeo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Braghiroli</surname><given-names>M. I.</given-names></name>, <name name-style="western"><surname>Holtved</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Ostoich</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H. R.</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mansoor</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W.-C.</given-names></name>, &#8230; <collab>CheckMate 648 Trial Investigators</collab>. (<year>2022</year>). <article-title>Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma</article-title>. <source>The New England Journal of Medicine</source>, <volume>386</volume>(<issue>5</issue>), <fpage>449</fpage>&#8211;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2111380</pub-id><pub-id pub-id-type="pmid">35108470</pub-id></mixed-citation></ref><ref id="R23"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ebert</surname><given-names>P. J. R.</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>McNamara</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Moskalenko</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Gould</surname><given-names>S. E.</given-names></name>, <name name-style="western"><surname>Maecker</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Irving</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Belvin</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name> (<year>2016</year>). <article-title>MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade</article-title>. <source>Immunity</source>, <volume>44</volume>(<issue>3</issue>), <fpage>609</fpage>&#8211;<lpage>621</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.024</pub-id><pub-id pub-id-type="pmid">26944201</pub-id></mixed-citation></ref><ref id="R24"><mixed-citation publication-type="journal"><name name-style="western"><surname>Flicek</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Amode</surname><given-names>M. R.</given-names></name>, <name name-style="western"><surname>Barrell</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Beal</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Brent</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Carvalho-Silva</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Clapham</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Coates</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Fairley</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gil</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Garc&#237;a-Gir&#243;n</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hourlier</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Juettemann</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>K&#228;h&#228;ri</surname><given-names>A. K.</given-names></name>, <name name-style="western"><surname>Keenan</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Searle</surname><given-names>S. M. J.</given-names></name> (<year>2013</year>). <article-title>Ensembl 2013</article-title>. <source>Nucleic Acids Research</source>, <volume>41</volume>(<issue>D1</issue>), <fpage>48</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1236</pub-id><pub-id pub-id-type="pmcid">PMC3531136</pub-id><pub-id pub-id-type="pmid">23203987</pub-id></mixed-citation></ref><ref id="R25"><mixed-citation publication-type="journal"><name name-style="western"><surname>Friedman</surname><given-names>J. H.</given-names></name> (<year>2001</year>). <article-title>Greedy function approximation: A gradient boosting machine</article-title>. <source>The Annals of Statistics</source>, <volume>29</volume>(<issue>5</issue>). <pub-id pub-id-type="doi">10.1214/aos/1013203451</pub-id></mixed-citation></ref><ref id="R26"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>L. Z.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Roszik</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bernatchez</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Woodman</surname><given-names>S. E.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>P.-L.</given-names></name>, <name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Allison</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Futreal</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wargo</surname><given-names>J. A.</given-names></name>, &amp; <name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name> (<year>2016</year>). <article-title>Loss of IFN-&#947; Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy</article-title>. <source>Cell</source>, <volume>167</volume>(<issue>2</issue>), <fpage>397</fpage>&#8211;<lpage>404.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.08.069</pub-id><pub-id pub-id-type="pmid">27667683</pub-id><pub-id pub-id-type="pmcid">PMC5088716</pub-id></mixed-citation></ref><ref id="R27"><mixed-citation publication-type="journal"><name name-style="western"><surname>Gide</surname><given-names>T. N.</given-names></name>, <name name-style="western"><surname>Quek</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Menzies</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Tasker</surname><given-names>A. T.</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Holst</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Madore</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>S. Y.</given-names></name>, <name name-style="western"><surname>Velickovic</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Wongchenko</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Carlino</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Guminski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Saw</surname><given-names>R. P. M.</given-names></name>, <name name-style="western"><surname>Pang</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>McGuire</surname><given-names>H. M.</given-names></name>, <name name-style="western"><surname>Palendira</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name>, &#8230; <name name-style="western"><surname>Wilmott</surname><given-names>J. S.</given-names></name> (<year>2019</year>). <article-title>Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy</article-title>. <source>Cancer Cell</source>, <volume>35</volume>(<issue>2</issue>), <fpage>238</fpage>&#8211;<lpage>255.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2019.01.003</pub-id><pub-id pub-id-type="pmid">30753825</pub-id></mixed-citation></ref><ref id="R28"><mixed-citation publication-type="journal"><name name-style="western"><surname>Glimcher</surname><given-names>L. H.</given-names></name>, &amp; <name name-style="western"><surname>Kara</surname><given-names>C. J.</given-names></name> (<year>1992</year>). <article-title>Sequences and factors: a guide to MHC class-II transcription</article-title>. <source>Annual Review of Immunology</source>, <volume>10</volume>, <fpage>13</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.iy.10.040192.000305</pub-id><pub-id pub-id-type="pmid">1590984</pub-id></mixed-citation></ref><ref id="R29"><mixed-citation publication-type="journal"><name name-style="western"><surname>Goel</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>DeCristo</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Watt</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>BrinJones</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sceneay</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B. B.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Ubellacker</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Metzger-Filho</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Hoog</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ellis</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>C. X.</given-names></name>, <name name-style="western"><surname>Ramm</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Krop</surname><given-names>I. E.</given-names></name>, <name name-style="western"><surname>Winer</surname><given-names>E. P.</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>T. M.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name>, <name name-style="western"><surname>McAllister</surname><given-names>S. S.</given-names></name>, &amp; <name name-style="western"><surname>Zhao</surname><given-names>J. J.</given-names></name> (<year>2017</year>). <article-title>CDK4/6 inhibition triggers anti-tumour immunity</article-title>. <source>Nature</source>, <volume>548</volume>(<issue>7668</issue>), <fpage>471</fpage>&#8211;<lpage>475</lpage>. <pub-id pub-id-type="doi">10.1038/nature23465</pub-id><pub-id pub-id-type="pmid">28813415</pub-id><pub-id pub-id-type="pmcid">PMC5570667</pub-id></mixed-citation></ref><ref id="R30"><mixed-citation publication-type="journal"><name name-style="western"><surname>Graham</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chilton-MacNeill</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zielenska</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Somers</surname><given-names>G. R.</given-names></name> (<year>2012</year>). <article-title>The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas</article-title>. <source>Human Pathology</source>, <volume>43</volume>(<issue>2</issue>), <fpage>180</fpage>&#8211;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2011.04.023</pub-id><pub-id pub-id-type="pmid">21813156</pub-id></mixed-citation></ref><ref id="R31"><mixed-citation publication-type="journal"><name name-style="western"><surname>Grasso</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>Giannakis</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>D. K.</given-names></name>, <name name-style="western"><surname>Hamada</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>X. J.</given-names></name>, <name name-style="western"><surname>Quist</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Nishihara</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>Z. R.</given-names></name>, <name name-style="western"><surname>Inamura</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Morikawa</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nosho</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Abril-Rodriguez</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Connolly</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Escuin-Ordinas</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Geybels</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Grady</surname><given-names>W. M.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Peters</surname><given-names>U.</given-names></name> (<year>2018</year>). <article-title>Genetic Mechanisms of Immune Evasion in Colorectal Cancer</article-title>. <source>Cancer Discovery</source>, <volume>8</volume>(<issue>6</issue>), <fpage>730</fpage>&#8211;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1327</pub-id><pub-id pub-id-type="pmid">29510987</pub-id><pub-id pub-id-type="pmcid">PMC5984687</pub-id></mixed-citation></ref><ref id="R32"><mixed-citation publication-type="journal"><name name-style="western"><surname>Grasso</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>Tsoi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Onyshchenko</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Abril-Rodriguez</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Ross-Macdonald</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Wind-Rotolo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Champhekar</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Medina</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Torrejon</surname><given-names>D. Y.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>D. S.</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y. J.</given-names></name>, <name name-style="western"><surname>Puig-Saus</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Vega-Crespo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Quist</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Martignier</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Luke</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name>, &#8230; <name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name> (<year>2020</year>). <article-title>Conserved Interferon-&#947; Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma</article-title>. <source>Cancer Cell</source>, <volume>38</volume>(<issue>4</issue>), <fpage>500</fpage>&#8211;<lpage>515.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.08.005</pub-id><pub-id pub-id-type="pmid">32916126</pub-id><pub-id pub-id-type="pmcid">PMC7872287</pub-id></mixed-citation></ref><ref id="R33"><mixed-citation publication-type="webpage"><name name-style="western"><surname>Greenwell</surname><given-names>B.</given-names></name> (<year>2021</year>). <source>fastshap: Fast Approximate Shapley Values (R package version 0.0.7)</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=fastshap" ext-link-type="uri">https://CRAN.R-project.org/package=fastshap</ext-link></comment></mixed-citation></ref><ref id="R34"><mixed-citation publication-type="book"><name name-style="western"><surname>Hastie</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tibshirani</surname><given-names>R.</given-names></name>, &amp; <name name-style="western"><surname>Friedman</surname><given-names>J.</given-names></name> (<year>2009</year>). <source>The Elements of Statistical Learning</source>. <publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc>. <pub-id pub-id-type="doi">10.1007/978-0-387-84858-7</pub-id></mixed-citation></ref><ref id="R35"><mixed-citation publication-type="journal"><name name-style="western"><surname>Heagerty</surname><given-names>P. J.</given-names></name>, &amp; <name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name> (<year>2005</year>). <article-title>Survival model predictive accuracy and ROC curves</article-title>. <source>Biometrics</source>, <volume>61</volume>(<issue>1</issue>), <fpage>92</fpage>&#8211;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1111/j.0006-341X.2005.030814.x</pub-id><pub-id pub-id-type="pmid">15737082</pub-id></mixed-citation></ref><ref id="R36"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hellmann</surname><given-names>M. D.</given-names></name>, <name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bernabe Caro</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zurawski</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S.-W.</given-names></name>, <name name-style="western"><surname>Carcereny Costa</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Alexandru</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lupinacci</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>de la Mora Jimenez</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sakai</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Vergnenegre</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Syrigos</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Reck</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Borghaei</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Brahmer</surname><given-names>J. R.</given-names></name>, &#8230; <name name-style="western"><surname>Ramalingam</surname><given-names>S. S.</given-names></name> (<year>2019</year>). <article-title>Nivolumab plus Ipilimumab in Advanced Non&#8211;Small-Cell Lung Cancer</article-title>. <source>New England Journal of Medicine</source>, <volume>381</volume>(<issue>21</issue>), <fpage>2020</fpage>&#8211;<lpage>2031</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910231</pub-id><pub-id pub-id-type="pmid">31562796</pub-id></mixed-citation></ref><ref id="R37"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hendrickson</surname><given-names>P. G.</given-names></name>, <name name-style="western"><surname>Dor&#225;is</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Grow</surname><given-names>E. J.</given-names></name>, <name name-style="western"><surname>Whiddon</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>J.-W.</given-names></name>, <name name-style="western"><surname>Wike</surname><given-names>C. L.</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>B. D.</given-names></name>, <name name-style="western"><surname>Pflueger</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Emery</surname><given-names>B. R.</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>A. L.</given-names></name>, <name name-style="western"><surname>Nix</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>C. M.</given-names></name>, <name name-style="western"><surname>Tapscott</surname><given-names>S. J.</given-names></name>, <name name-style="western"><surname>Carrell</surname><given-names>D. T.</given-names></name>, &amp; <name name-style="western"><surname>Cairns</surname><given-names>B. R.</given-names></name> (<year>2017</year>). <article-title>Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons</article-title>. <source>Nature Genetics</source>, <volume>49</volume>(<issue>6</issue>), <fpage>925</fpage>&#8211;<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3844</pub-id><pub-id pub-id-type="pmid">28459457</pub-id><pub-id pub-id-type="pmcid">PMC5703070</pub-id></mixed-citation></ref><ref id="R38"><mixed-citation publication-type="journal"><name name-style="western"><surname>Himeda</surname><given-names>C. L.</given-names></name>, &amp; <name name-style="western"><surname>Jones</surname><given-names>P. L.</given-names></name> (<year>2019</year>). <article-title>The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy</article-title>. <source>Annual Review of Genomics and Human Genetics</source>, <volume>20</volume>, <fpage>265</fpage>&#8211;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-genom-083118-014933</pub-id><pub-id pub-id-type="pmid">31018108</pub-id></mixed-citation></ref><ref id="R39"><mixed-citation publication-type="journal"><name name-style="western"><surname>Hsich</surname><given-names>E. M.</given-names></name>, <name name-style="western"><surname>Thuita</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>McNamara</surname><given-names>D. M.</given-names></name>, <name name-style="western"><surname>Rogers</surname><given-names>J. G.</given-names></name>, <name name-style="western"><surname>Valapour</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Goldberg</surname><given-names>L. R.</given-names></name>, <name name-style="western"><surname>Yancy</surname><given-names>C. W.</given-names></name>, <name name-style="western"><surname>Blackstone</surname><given-names>E. H.</given-names></name>, <name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, &amp; <collab>Transplantation of HEarts to MaxImize Survival (THEMIS) Investigators</collab>. (<year>2019</year>). <article-title>Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality</article-title>. <source>American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons</source>, <volume>19</volume>(<issue>7</issue>), <fpage>2067</fpage>&#8211;<lpage>2076</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.15265</pub-id><pub-id pub-id-type="pmid">30659754</pub-id><pub-id pub-id-type="pmcid">PMC6591021</pub-id></mixed-citation></ref><ref id="R40"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name> (<year>2007</year>). <article-title>Variable importance in binary regression trees and forests</article-title>. <source>Electronic Journal of Statistics</source>, <volume>1</volume>(<issue>none</issue>). <pub-id pub-id-type="doi">10.1214/07-EJS039</pub-id></mixed-citation></ref><ref id="R41"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Blackstone</surname><given-names>E. H.</given-names></name>, <name name-style="western"><surname>Apperson-Hansen</surname><given-names>C.</given-names></name>, &amp; <name name-style="western"><surname>Rice</surname><given-names>T. W.</given-names></name> (<year>2009</year>). <article-title>A novel approach to cancer staging: application to esophageal cancer</article-title>. <source>Biostatistics (Oxford, England)</source>, <volume>10</volume>(<issue>4</issue>), <fpage>603</fpage>&#8211;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1093/biostatistics/kxp016</pub-id><pub-id pub-id-type="pmid">19502615</pub-id><pub-id pub-id-type="pmcid">PMC3590074</pub-id></mixed-citation></ref><ref id="R42"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kogalur</surname><given-names>U. B.</given-names></name>, <name name-style="western"><surname>Blackstone</surname><given-names>E. H.</given-names></name>, &amp; <name name-style="western"><surname>Lauer</surname><given-names>M. S.</given-names></name> (<year>2008</year>). <article-title>Random survival forests</article-title>. <source>The Annals of Applied Statistics</source>, <volume>2</volume>(<issue>3</issue>). <pub-id pub-id-type="doi">10.1214/08-AOAS169</pub-id></mixed-citation></ref><ref id="R43"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kogalur</surname><given-names>U. B.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>, &amp; <name name-style="western"><surname>Minn</surname><given-names>A. J.</given-names></name> (<year>2011</year>). <article-title>Random survival forests for high-dimensional data</article-title>. <source>Statistical Analysis and Data Mining: The ASA Data Science Journal</source>, <volume>4</volume>(<issue>1</issue>), <fpage>115</fpage>&#8211;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1002/sam.10103</pub-id></mixed-citation></ref><ref id="R44"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kogalur</surname><given-names>U. B.</given-names></name>, <name name-style="western"><surname>Gorodeski</surname><given-names>E. Z.</given-names></name>, <name name-style="western"><surname>Minn</surname><given-names>A. J.</given-names></name>, &amp; <name name-style="western"><surname>Lauer</surname><given-names>M. S.</given-names></name> (<year>2010</year>). <article-title>High-Dimensional Variable Selection for Survival Data</article-title>. <source>Journal of the American Statistical Association</source>, <volume>105</volume>(<issue>489</issue>), <fpage>205</fpage>&#8211;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1198/jasa.2009.tm08622</pub-id></mixed-citation></ref><ref id="R45"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, &amp; <name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name> (<year>2019</year>). <article-title>Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival</article-title>. <source>Statistics in Medicine</source>, <volume>38</volume>(<issue>4</issue>), <fpage>558</fpage>&#8211;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1002/sim.7803</pub-id><pub-id pub-id-type="pmid">29869423</pub-id><pub-id pub-id-type="pmcid">PMC6279615</pub-id></mixed-citation></ref><ref id="R46"><mixed-citation publication-type="journal"><name name-style="western"><surname>Italiano</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>Y. S.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Singer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Maki</surname><given-names>R. G.</given-names></name>, <name name-style="western"><surname>Coindre</surname><given-names>J.-M.</given-names></name>, &amp; <name name-style="western"><surname>Antonescu</surname><given-names>C. R.</given-names></name> (<year>2012</year>). <article-title>High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas</article-title>. <source>Genes, Chromosomes and Cancer</source>, <volume>51</volume>(<issue>3</issue>), <fpage>207</fpage>&#8211;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.20945</pub-id><pub-id pub-id-type="pmid">22072439</pub-id><pub-id pub-id-type="pmcid">PMC3404826</pub-id></mixed-citation></ref><ref id="R47"><mixed-citation publication-type="journal"><name name-style="western"><surname>Janitza</surname><given-names>S.</given-names></name>, &amp; <name name-style="western"><surname>Hornung</surname><given-names>R.</given-names></name> (<year>2018</year>). <article-title>On the overestimation of random forest&#8217;s out-of-bag error</article-title>. <source>PloS One</source>, <volume>13</volume>(<issue>8</issue>), <fpage>e0201904</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0201904</pub-id><pub-id pub-id-type="pmid">30080866</pub-id><pub-id pub-id-type="pmcid">PMC6078316</pub-id></mixed-citation></ref><ref id="R48"><mixed-citation publication-type="journal"><name name-style="western"><surname>Jerby-Arnon</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Cuoco</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Rodman</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>M.-J.</given-names></name>, <name name-style="western"><surname>Melms</surname><given-names>J. C.</given-names></name>, <name name-style="western"><surname>Leeson</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kanodia</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>J.-R.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Rabasha</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Margolais</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Ashenberg</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Ott</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Buchbinder</surname><given-names>E. I.</given-names></name>, <name name-style="western"><surname>Haq</surname><given-names>R.</given-names></name>, &#8230; <name name-style="western"><surname>Regev</surname><given-names>A.</given-names></name> (<year>2018</year>). <article-title>A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade</article-title>. <source>Cell</source>, <volume>175</volume>(<issue>4</issue>), <fpage>984</fpage>&#8211;<lpage>997.e24</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.09.006</pub-id><pub-id pub-id-type="pmid">30388455</pub-id><pub-id pub-id-type="pmcid">PMC6410377</pub-id></mixed-citation></ref><ref id="R49"><mixed-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sahu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Traugh</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>G. J.</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Wucherpfennig</surname><given-names>K. W.</given-names></name>, &amp; <name name-style="western"><surname>Liu</surname><given-names>X. S.</given-names></name> (<year>2018</year>). <article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title>. <source>Nature Medicine</source>, <volume>24</volume>(<issue>10</issue>), <fpage>1550</fpage>&#8211;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0136-1</pub-id><pub-id pub-id-type="pmcid">PMC6487502</pub-id><pub-id pub-id-type="pmid">30127393</pub-id></mixed-citation></ref><ref id="R50"><mixed-citation publication-type="journal"><name name-style="western"><surname>Johnson</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Bullock</surname><given-names>B. L.</given-names></name>, <name name-style="western"><surname>Neuwelt</surname><given-names>A. J.</given-names></name>, <name name-style="western"><surname>Poczobutt</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Kaspar</surname><given-names>R. E.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H. Y.</given-names></name>, <name name-style="western"><surname>Kwak</surname><given-names>J. W.</given-names></name>, <name name-style="western"><surname>Hopp</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Weiser-Evans</surname><given-names>M. C. M.</given-names></name>, <name name-style="western"><surname>Heasley</surname><given-names>L. E.</given-names></name>, <name name-style="western"><surname>Schenk</surname><given-names>E. L.</given-names></name>, <name name-style="western"><surname>Clambey</surname><given-names>E. T.</given-names></name>, &amp; <name name-style="western"><surname>Nemenoff</surname><given-names>R. A.</given-names></name> (<year>2020</year>). <article-title>Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma</article-title>. <source>Journal of Immunology (Baltimore, Md. : 1950)</source>, <volume>204</volume>(<issue>8</issue>), <fpage>2295</fpage>&#8211;<lpage>2307</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1900778</pub-id><pub-id pub-id-type="pmid">32179637</pub-id><pub-id pub-id-type="pmcid">PMC7472648</pub-id></mixed-citation></ref><ref id="R51"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kalbasi</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name> (<year>2020</year>). <article-title>Tumour-intrinsic resistance to immune checkpoint blockade</article-title>. <source>Nature Reviews. Immunology</source>, <volume>20</volume>(<issue>1</issue>), <fpage>25</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-019-0218-4</pub-id><pub-id pub-id-type="pmcid">PMC8499690</pub-id><pub-id pub-id-type="pmid">31570880</pub-id></mixed-citation></ref><ref id="R52"><mixed-citation publication-type="webpage"><name name-style="western"><surname>Kassambara</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kosinski</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Biecek</surname><given-names>P.</given-names></name> (<year>2021</year>). <source>survminer: Drawing Survival Curves using &#8220;ggplot2&#8221; (R package version 0.4.9)</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=survminer" ext-link-type="uri">https://CRAN.R-project.org/package=survminer</ext-link></comment></mixed-citation></ref><ref id="R53"><mixed-citation publication-type="journal"><name name-style="western"><surname>Katz</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>E. T.</given-names></name>, <name name-style="western"><surname>Airoldi</surname><given-names>E. M.</given-names></name>, &amp; <name name-style="western"><surname>Burge</surname><given-names>C. B.</given-names></name> (<year>2010</year>). <article-title>Analysis and design of RNA sequencing experiments for identifying isoform regulation</article-title>. <source>Nature Methods</source>, <volume>7</volume>(<issue>12</issue>), <fpage>1009</fpage>&#8211;<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1528</pub-id><pub-id pub-id-type="pmid">21057496</pub-id><pub-id pub-id-type="pmcid">PMC3037023</pub-id></mixed-citation></ref><ref id="R54"><mixed-citation publication-type="journal"><name name-style="western"><surname>Kawamura-Saito</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Kaneko</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kawaguchi</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kanda</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Mukai</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Gotoh</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Motoi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Fukayama</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Aburatani</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Takizawa</surname><given-names>T.</given-names></name>, &amp; <name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name> (<year>2006</year>). <article-title>Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation</article-title>. <source>Human Molecular Genetics</source>, <volume>15</volume>(<issue>13</issue>), <fpage>2125</fpage>&#8211;<lpage>2137</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddl136</pub-id><pub-id pub-id-type="pmid">16717057</pub-id></mixed-citation></ref><ref id="R55"><mixed-citation publication-type="journal"><name name-style="western"><surname>Klein</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Kee</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Nagrial</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Markman</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Underhill</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Michael</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jackett</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Lum</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Behren</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tebbutt</surname><given-names>N. C.</given-names></name>, <name name-style="western"><surname>Carlino</surname><given-names>M. S.</given-names></name>, &amp; <name name-style="western"><surname>Cebon</surname><given-names>J.</given-names></name> (<year>2020</year>). <article-title>Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial</article-title>. <source>JAMA Oncology</source>, <volume>6</volume>(<issue>9</issue>), <fpage>1405</fpage>&#8211;<lpage>1409</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.2814</pub-id><pub-id pub-id-type="pmid">32729929</pub-id><pub-id pub-id-type="pmcid">PMC7393585</pub-id></mixed-citation></ref><ref id="R56"><mixed-citation publication-type="journal"><name name-style="western"><surname>Krishnan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kasinath</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>High</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name>, &amp; <name name-style="western"><surname>Teply</surname><given-names>B. A.</given-names></name> (<year>2022</year>). <article-title>Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors</article-title>. <source>JCO Oncology Practice</source>, <volume>18</volume>(<issue>1</issue>), <fpage>e175</fpage>&#8211;<lpage>e182</lpage>. <pub-id pub-id-type="doi">10.1200/OP.20.01055</pub-id><pub-id pub-id-type="pmid">34351819</pub-id></mixed-citation></ref><ref id="R57"><mixed-citation publication-type="webpage"><name name-style="western"><surname>Kuhn</surname><given-names>M.</given-names></name> (<year>2022</year>). <source>caret: Classification and Regression Training (R package version 6.0&#8211;93)</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=caret" ext-link-type="uri">https://CRAN.R-project.org/package=caret</ext-link></comment></mixed-citation></ref><ref id="R58"><mixed-citation publication-type="journal"><name name-style="western"><surname>Langmead</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Trapnell</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pop</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Salzberg</surname><given-names>S. L.</given-names></name> (<year>2009</year>). <article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title>. <source>Genome Biology</source>, <volume>10</volume>(<issue>3</issue>). <pub-id pub-id-type="doi">10.1186/gb-2009-10-3-r25</pub-id><pub-id pub-id-type="pmcid">PMC2690996</pub-id><pub-id pub-id-type="pmid">19261174</pub-id></mixed-citation></ref><ref id="R59"><mixed-citation publication-type="journal"><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name>, <name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lao</surname><given-names>C. D.</given-names></name>, <name name-style="western"><surname>Cowey</surname><given-names>C. L.</given-names></name>, <name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wagstaff</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ferrucci</surname><given-names>P. F.</given-names></name>, <name name-style="western"><surname>Smylie</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hogg</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>M&#225;rquez-Rodas</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Guidoboni</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Maio</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sch&#246;ffski</surname><given-names>P.</given-names></name>, &#8230; <name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name> (<year>2019</year>). <article-title>Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</article-title>. <source>The New England Journal of Medicine</source>, <volume>381</volume>(<issue>16</issue>), <fpage>1535</fpage>&#8211;<lpage>1546</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></mixed-citation></ref><ref id="R60"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Navarro</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lianoglou</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Haley</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Totpal</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Koeppen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Caplazi</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>McBride</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Grogan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Javinal</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Yauch</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Irving</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Belvin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J. M.</given-names></name>, &amp; <name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name> (<year>2017</year>). <article-title>Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice</article-title>. <source>Nature Communications</source>, <volume>8</volume>(<issue>1</issue>), <fpage>14572</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14572</pub-id><pub-id pub-id-type="pmcid">PMC5321797</pub-id><pub-id pub-id-type="pmid">28220772</pub-id></mixed-citation></ref><ref id="R61"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name>, <name name-style="western"><surname>Shklovskaya</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>S. Y.</given-names></name>, <name name-style="western"><surname>Carlino</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Menzies</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pedersen</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Irvine</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Alavi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J. Y. H.</given-names></name>, <name name-style="western"><surname>Strbenac</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Saw</surname><given-names>R. P. M.</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name>, <name name-style="western"><surname>Wilmott</surname><given-names>J. S.</given-names></name>, <name name-style="western"><surname>Scolyer</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>G. v</given-names></name>, <name name-style="western"><surname>Kefford</surname><given-names>R. F.</given-names></name>, &amp; <name name-style="western"><surname>Rizos</surname><given-names>H.</given-names></name> (<year>2020</year>). <article-title>Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition</article-title>. <source>Nature Communications</source>, <volume>11</volume>(<issue>1</issue>), <fpage>1897</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-15726-7</pub-id><pub-id pub-id-type="pmcid">PMC7171183</pub-id><pub-id pub-id-type="pmid">32312968</pub-id></mixed-citation></ref><ref id="R62"><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name>, &amp; <name name-style="western"><surname>Dewey</surname><given-names>C. N.</given-names></name> (<year>2011</year>). <article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title>. <source>BMC Bioinformatics</source>, <volume>12</volume>, <fpage>323</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id><pub-id pub-id-type="pmcid">PMC3163565</pub-id></mixed-citation></ref><ref id="R63"><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Handsaker</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Wysoker</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Fennell</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Homer</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Marth</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Durbin</surname><given-names>R.</given-names></name>, &amp; <collab>1000 Genome Project Data Processing Subgroup</collab>. (<year>2009</year>). <article-title>The Sequence Alignment/Map format and SAMtools</article-title>. <source>Bioinformatics (Oxford, England)</source>, <volume>25</volume>(<issue>16</issue>), <fpage>2078</fpage>&#8211;<lpage>2079</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id><pub-id pub-id-type="pmcid">PMC2723002</pub-id></mixed-citation></ref><ref id="R64"><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Y.-Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>C.-Q.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.-M.</given-names></name>, <name name-style="western"><surname>Jokitalo</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shu</surname><given-names>H.-B.</given-names></name>, &amp; <name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name> (<year>2016</year>). <article-title>The tumor suppressor PTEN has a critical role in antiviral innate immunity</article-title>. <source>Nature Immunology</source>, <volume>17</volume>(<issue>3</issue>), <fpage>241</fpage>&#8211;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3311</pub-id><pub-id pub-id-type="pmid">26692175</pub-id></mixed-citation></ref><ref id="R65"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lilljebj&#246;rn</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Henningsson</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hyrenius-Wittsten</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Olsson</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Orsmark-Pietras</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>von Palffy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Askmyr</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rissler</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Schrappe</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Cario</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Castor</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pronk</surname><given-names>C. J. H.</given-names></name>, <name name-style="western"><surname>Behrendtz</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mitelman</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Paulsson</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>A. K.</given-names></name>, <name name-style="western"><surname>Fontes</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Fioretos</surname><given-names>T.</given-names></name> (<year>2016</year>). <article-title>Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia</article-title>. <source>Nature Communications</source>, <volume>7</volume>, <fpage>11790</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11790</pub-id><pub-id pub-id-type="pmcid">PMC4897744</pub-id><pub-id pub-id-type="pmid">27265895</pub-id></mixed-citation></ref><ref id="R66"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hurt</surname><given-names>E. M.</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>M. D.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Vatan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Szeliga</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Herbst</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Harms</surname><given-names>P. W.</given-names></name>, <name name-style="western"><surname>Fecher</surname><given-names>L. A.</given-names></name>, <name name-style="western"><surname>Vats</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Lao</surname><given-names>C. D.</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>T. S.</given-names></name>, <name name-style="western"><surname>Wicha</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hamanishi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Mandai</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kryczek</surname><given-names>I.</given-names></name>, &amp; <name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name> (<year>2018</year>). <article-title>Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression</article-title>. <source>The Journal of Clinical Investigation</source>, <volume>128</volume>(<issue>2</issue>), <fpage>805</fpage>&#8211;<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1172/JCI96113</pub-id><pub-id pub-id-type="pmid">29337305</pub-id><pub-id pub-id-type="pmcid">PMC5785251</pub-id></mixed-citation></ref><ref id="R67"><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>Y.-F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B.-Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.-N.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>J.-Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B.-S.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J.-F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M.-J.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y.-J.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z.-G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y.-M.</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>X.-Q.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z.-X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J.-M.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, &#8230; <name name-style="western"><surname>Chen</surname><given-names>S.-J.</given-names></name> (<year>2016</year>). <article-title>Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia</article-title>. <source>EBioMedicine</source>, <volume>8</volume>, <fpage>173</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.04.038</pub-id><pub-id pub-id-type="pmid">27428428</pub-id><pub-id pub-id-type="pmcid">PMC4919728</pub-id></mixed-citation></ref><ref id="R68"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lundberg</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Erion</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>DeGrave</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Prutkin</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Himmelfarb</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bansal</surname><given-names>N.</given-names></name>, &amp; <name name-style="western"><surname>Lee</surname><given-names>S.-I.</given-names></name> (<year>2020</year>). <article-title>From Local Explanations to Global Understanding with Explainable AI for Trees</article-title>. <source>Nature Machine Intelligence</source>, <volume>2</volume>(<issue>1</issue>), <fpage>56</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-019-0138-9</pub-id><pub-id pub-id-type="pmcid">PMC7326367</pub-id><pub-id pub-id-type="pmid">32607472</pub-id></mixed-citation></ref><ref id="R69"><mixed-citation publication-type="journal"><name name-style="western"><surname>Lundberg</surname><given-names>S. M.</given-names></name>, &amp; <name name-style="western"><surname>Lee</surname><given-names>S.-I.</given-names></name> (<year>2017</year>). <article-title>A Unified Approach to Interpreting Model Predictions</article-title>. <source>Advances in Neural Information Processing Systems</source>, <volume>30</volume>.</mixed-citation></ref><ref id="R70"><mixed-citation publication-type="other"><name name-style="western"><surname>Maksymiuk</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gosiewska</surname><given-names>A.</given-names></name>, &amp; <name name-style="western"><surname>Biecek</surname><given-names>P.</given-names></name> (<year>2020</year>). <source>Landscape of R packages for eXplainable Artificial Intelligence</source>.</mixed-citation></ref><ref id="R71"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mariathasan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Turley</surname><given-names>S. J.</given-names></name>, <name name-style="western"><surname>Nickles</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Castiglioni</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Kadel</surname><given-names>E. E.</given-names></name>, <name name-style="western"><surname>Koeppen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Astarita</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Cubas</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Jhunjhunwala</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Banchereau</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chalouni</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Ziai</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>&#350;enbabao&#287;lu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Santoro</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sheinson</surname><given-names>D.</given-names></name>, &#8230; <name name-style="western"><surname>Powles</surname><given-names>T.</given-names></name> (<year>2018</year>). <article-title>TGF&#946; attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells</article-title>. <source>Nature</source>, <volume>554</volume>(<issue>7693</issue>), <fpage>544</fpage>&#8211;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1038/nature25501</pub-id><pub-id pub-id-type="pmid">29443960</pub-id><pub-id pub-id-type="pmcid">PMC6028240</pub-id></mixed-citation></ref><ref id="R72"><mixed-citation publication-type="journal"><name name-style="western"><surname>Masternak</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Muhlethaler-Mottet</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Villard</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zufferey</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Steimle</surname><given-names>V.</given-names></name>, &amp; <name name-style="western"><surname>Reith</surname><given-names>W.</given-names></name> (<year>2000</year>). <article-title>CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex</article-title>. <source>Genes &amp; Development</source>, <volume>14</volume>(<issue>9</issue>), <fpage>1156</fpage>&#8211;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">10809673</pub-id><pub-id pub-id-type="pmcid">PMC316580</pub-id></mixed-citation></ref><ref id="R73"><mixed-citation publication-type="journal"><name name-style="western"><surname>McGranahan</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Furness</surname><given-names>A. J. S.</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ramskov</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lyngaa</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Saini</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Jamal-Hanjani</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>G. A.</given-names></name>, <name name-style="western"><surname>Birkbak</surname><given-names>N. J.</given-names></name>, <name name-style="western"><surname>Hiley</surname><given-names>C. T.</given-names></name>, <name name-style="western"><surname>Watkins</surname><given-names>T. B. K.</given-names></name>, <name name-style="western"><surname>Shafi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Murugaesu</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Mitter</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Akarca</surname><given-names>A. U.</given-names></name>, <name name-style="western"><surname>Linares</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Marafioti</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>J. Y.</given-names></name>, <name name-style="western"><surname>van Allen</surname><given-names>E. M.</given-names></name>, &#8230; <name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name> (<year>2016</year>). <article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title>. <source>Science (New York, N.Y.)</source>, <volume>351</volume>(<issue>6280</issue>), <fpage>1463</fpage>&#8211;<lpage>1469</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf1490</pub-id><pub-id pub-id-type="pmid">26940869</pub-id><pub-id pub-id-type="pmcid">PMC4984254</pub-id></mixed-citation></ref><ref id="R74"><mixed-citation publication-type="journal"><name name-style="western"><surname>Meyer</surname><given-names>L. R.</given-names></name>, <name name-style="western"><surname>Zweig</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Hinrichs</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Karolchik</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kuhn</surname><given-names>R. M.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sloan</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Rosenbloom</surname><given-names>K. R.</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rhead</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Raney</surname><given-names>B. J.</given-names></name>, <name name-style="western"><surname>Pohl</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Malladi</surname><given-names>V. S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C. H.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>B. T.</given-names></name>, <name name-style="western"><surname>Learned</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kirkup</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Heitner</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Kent</surname><given-names>W. J.</given-names></name> (<year>2013</year>). <article-title>The UCSC Genome Browser database: Extensions and updates 2013</article-title>. <source>Nucleic Acids Research</source>, <volume>41</volume>(<issue>D1</issue>), <fpage>64</fpage>&#8211;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1048</pub-id><pub-id pub-id-type="pmcid">PMC3531082</pub-id><pub-id pub-id-type="pmid">23155063</pub-id></mixed-citation></ref><ref id="R75"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mitchell</surname><given-names>M. W.</given-names></name> (<year>2011</year>). <article-title>Bias of the Random Forest Out-of-Bag (OOB) Error for Certain Input Parameters</article-title>. <source>Open Journal of Statistics</source>, <volume>01</volume>(<issue>03</issue>), <fpage>205</fpage>&#8211;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.4236/ojs.2011.13024</pub-id></mixed-citation></ref><ref id="R76"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mogensen</surname><given-names>U. B.</given-names></name>, <name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, &amp; <name name-style="western"><surname>Gerds</surname><given-names>T. A.</given-names></name> (<year>2012</year>). <article-title>Evaluating Random Forests for Survival Analysis using Prediction Error Curves</article-title>. <source>Journal of Statistical Software</source>, <volume>50</volume>(<issue>11</issue>), <fpage>1</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v050.i11</pub-id><pub-id pub-id-type="pmid">25317082</pub-id><pub-id pub-id-type="pmcid">PMC4194196</pub-id></mixed-citation></ref><ref id="R77"><mixed-citation publication-type="journal"><name name-style="western"><surname>Mortazavi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>McCue</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Schaeffer</surname><given-names>L.</given-names></name>, &amp; <name name-style="western"><surname>Wold</surname><given-names>B.</given-names></name> (<year>2008</year>). <article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title>. <source>Nature Methods</source>, <volume>5</volume>(<issue>7</issue>), <fpage>621</fpage>&#8211;<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id><pub-id pub-id-type="pmid">18516045</pub-id></mixed-citation></ref><ref id="R78"><mixed-citation publication-type="journal"><name name-style="western"><surname>Motzer</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Escudier</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>George</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hammers</surname><given-names>H. J.</given-names></name>, <name name-style="western"><surname>Srinivas</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tykodi</surname><given-names>S. S.</given-names></name>, <name name-style="western"><surname>Sosman</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Plimack</surname><given-names>E. R.</given-names></name>, <name name-style="western"><surname>Procopio</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>McDermott</surname><given-names>D. F.</given-names></name>, <name name-style="western"><surname>Castellano</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Choueiri</surname><given-names>T. K.</given-names></name>, <name name-style="western"><surname>Donskov</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Gurney</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Oudard</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Richardet</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Peltola</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Alva</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Carducci</surname><given-names>M.</given-names></name>, &#8230; <name name-style="western"><surname>Tannir</surname><given-names>N. M.</given-names></name> (<year>2020</year>). <article-title>Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial</article-title>. <source>Cancer</source>, <volume>126</volume>(<issue>18</issue>), <fpage>4156</fpage>&#8211;<lpage>4167</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.33033</pub-id><pub-id pub-id-type="pmid">32673417</pub-id><pub-id pub-id-type="pmcid">PMC8415096</pub-id></mixed-citation></ref><ref id="R79"><mixed-citation publication-type="journal"><name name-style="western"><surname>Nagarsheth</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Wicha</surname><given-names>M. S.</given-names></name>, &amp; <name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name> (<year>2017</year>). <article-title>Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</article-title>. <source>Nature Reviews. Immunology</source>, <volume>17</volume>(<issue>9</issue>), <fpage>559</fpage>&#8211;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.49</pub-id><pub-id pub-id-type="pmcid">PMC5731833</pub-id><pub-id pub-id-type="pmid">28555670</pub-id></mixed-citation></ref><ref id="R80"><mixed-citation publication-type="journal"><name name-style="western"><surname>Newell</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Pires da Silva</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Menzies</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Wilmott</surname><given-names>J. S.</given-names></name>, <name name-style="western"><surname>Addala</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Carlino</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Rizos</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Nones</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Lakis</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Kazakoff</surname><given-names>S. H.</given-names></name>, <name name-style="western"><surname>Mukhopadhyay</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>P. M.</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Koufariotis</surname><given-names>L. T.</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Blank</surname><given-names>C. U.</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>J. F.</given-names></name>, &#8230; <name name-style="western"><surname>Long</surname><given-names>G. v.</given-names></name> (<year>2022</year>). <article-title>Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance</article-title>. <source>Cancer Cell</source>, <volume>40</volume>(<issue>1</issue>), <fpage>88</fpage>&#8211;<lpage>102.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2021.11.012</pub-id><pub-id pub-id-type="pmid">34951955</pub-id></mixed-citation></ref><ref id="R81"><mixed-citation publication-type="journal"><name name-style="western"><surname>Nguyen</surname><given-names>T.-T.</given-names></name>, <name name-style="western"><surname>Ramsay</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ahanfeshar-Adams</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lajoie</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Alain</surname><given-names>T.</given-names></name>, &amp; <name name-style="western"><surname>Watson</surname><given-names>I. R.</given-names></name> (<year>2021</year>). <article-title>Mutations in the IFN&#947;-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment</article-title>. <source>Clinical Cancer Research : An Official Journal of the American Association for Cancer Research</source>, <volume>27</volume>(<issue>12</issue>), <fpage>3432</fpage>&#8211;<lpage>3442</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3365</pub-id><pub-id pub-id-type="pmid">33593882</pub-id></mixed-citation></ref><ref id="R82"><mixed-citation publication-type="journal"><name name-style="western"><surname>Noguchi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Gubin</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Arthur</surname><given-names>C. D.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S. H.</given-names></name>, <name name-style="western"><surname>Hundal</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Selby</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Graziano</surname><given-names>R. F.</given-names></name>, <name name-style="western"><surname>Mardis</surname><given-names>E. R.</given-names></name>, <name name-style="western"><surname>Korman</surname><given-names>A. J.</given-names></name>, &amp; <name name-style="western"><surname>Schreiber</surname><given-names>R. D.</given-names></name> (<year>2017</year>). <article-title>Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape</article-title>. <source>Cancer Immunology Research</source>, <volume>5</volume>(<issue>2</issue>), <fpage>106</fpage>&#8211;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0391</pub-id><pub-id pub-id-type="pmid">28073774</pub-id><pub-id pub-id-type="pmcid">PMC5510474</pub-id></mixed-citation></ref><ref id="R83"><mixed-citation publication-type="journal"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>R. C.</given-names></name>, <name name-style="western"><surname>Ishwaran</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Szczotka-Flynn</surname><given-names>L. B.</given-names></name>, <name name-style="western"><surname>Lass</surname><given-names>J. H.</given-names></name>, &amp; <collab>Cornea Preservation Time Study (CPTS) Group</collab>. (<year>2021</year>). <article-title>Random Survival Forests Analysis of Intraoperative Complications as Predictors of Descemet Stripping Automated Endothelial Keratoplasty Graft Failure in the Cornea Preservation Time Study</article-title>. <source>JAMA Ophthalmology</source>, <volume>139</volume>(<issue>2</issue>), <fpage>191</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.5743</pub-id><pub-id pub-id-type="pmid">33355637</pub-id><pub-id pub-id-type="pmcid">PMC7758826</pub-id></mixed-citation></ref><ref id="R84"><mixed-citation publication-type="journal"><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J. Q.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Malu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Creasy</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>McKenzie</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>L. J.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Mbofung</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lazar</surname><given-names>A. J.</given-names></name>, <name name-style="western"><surname>Torres-Cabala</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>Z. A.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>P.-L.</given-names></name>, <name name-style="western"><surname>Tieu</surname><given-names>T. N.</given-names></name>, &#8230; <name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name> (<year>2016</year>). <article-title>Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy</article-title>. <source>Cancer Discovery</source>, <volume>6</volume>(<issue>2</issue>), <fpage>202</fpage>&#8211;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0283</pub-id><pub-id pub-id-type="pmid">26645196</pub-id><pub-id pub-id-type="pmcid">PMC4744499</pub-id></mixed-citation></ref><ref id="R85"><mixed-citation publication-type="journal"><name name-style="western"><surname>Powles</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Eder</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Fine</surname><given-names>G. D.</given-names></name>, <name name-style="western"><surname>Braiteh</surname><given-names>F. S.</given-names></name>, <name name-style="western"><surname>Loriot</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cruz</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bellmunt</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Burris</surname><given-names>H. A.</given-names></name>, <name name-style="western"><surname>Petrylak</surname><given-names>D. P.</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Hegde</surname><given-names>P. S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>D. S.</given-names></name>, &amp; <name name-style="western"><surname>Vogelzang</surname><given-names>N. J.</given-names></name> (<year>2014</year>). <article-title>MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer</article-title>. <source>Nature</source>, <volume>515</volume>(<issue>7528</issue>), <fpage>558</fpage>&#8211;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1038/nature13904</pub-id><pub-id pub-id-type="pmid">25428503</pub-id></mixed-citation></ref><ref id="R86"><mixed-citation publication-type="journal"><name name-style="western"><surname>Preussner</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sreenivasan</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>G&#252;nther</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Engleitner</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>K&#252;nne</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Glatzel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rad</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Looso</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Braun</surname><given-names>T.</given-names></name>, &amp; <name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name> (<year>2018</year>). <article-title>Oncogenic Amplification of Zygotic Dux Factors in Regenerating p53-Deficient Muscle Stem Cells Defines a Molecular Cancer Subtype</article-title>. <source>Cell Stem Cell</source>, <volume>23</volume>(<issue>6</issue>), <fpage>794</fpage>&#8211;<lpage>805.e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2018.10.011</pub-id><pub-id pub-id-type="pmid">30449715</pub-id></mixed-citation></ref><ref id="R87"><mixed-citation publication-type="journal"><name name-style="western"><surname>Qian</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kham</surname><given-names>S. K.-Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Goodings</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>T.-N.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Moriyama</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Quah</surname><given-names>T. C.</given-names></name>, <name name-style="western"><surname>Ariffin</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bhojwani</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Yang</surname><given-names>J. J.</given-names></name> (<year>2017</year>). <article-title>Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP</article-title>. <source>Genome Research</source>, <volume>27</volume>(<issue>2</issue>), <fpage>185</fpage>&#8211;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1101/gr.209163.116</pub-id><pub-id pub-id-type="pmid">27903646</pub-id><pub-id pub-id-type="pmcid">PMC5287225</pub-id></mixed-citation></ref><ref id="R88"><mixed-citation publication-type="book"><collab>R Core Team</collab>. (<year>2022</year>). <source>R: A Language and Environment for Statistical Computing</source>. <publisher-name>R Foundation for Statistical Computing</publisher-name>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></comment></mixed-citation></ref><ref id="R89"><mixed-citation publication-type="journal"><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>W. H.</given-names></name>, <name name-style="western"><surname>Carlino</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>G. v</given-names></name>, <name name-style="western"><surname>Hodi</surname><given-names>F. S.</given-names></name>, <name name-style="western"><surname>Tsoi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Grasso</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>Mookerjee</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Ghori</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>B. H.</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>N.</given-names></name>, &amp; <name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name> (<year>2019</year>). <article-title>Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma</article-title>. <source>Nature Medicine</source>, <volume>25</volume>(<issue>6</issue>), <fpage>936</fpage>&#8211;<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0476-5</pub-id><pub-id pub-id-type="pmcid">PMC8562134</pub-id><pub-id pub-id-type="pmid">31171879</pub-id></mixed-citation></ref><ref id="R90"><mixed-citation publication-type="journal"><name name-style="western"><surname>Robinson</surname><given-names>D. R.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y.-M.</given-names></name>, <name name-style="western"><surname>Lonigro</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Vats</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Cobain</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Everett</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Rabban</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kumar-Sinha</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Raymond</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Schuetze</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Alva</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Siddiqui</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chugh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Worden</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zalupski</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Innis</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Mody</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Tomlins</surname><given-names>S. A.</given-names></name>, &#8230; <name name-style="western"><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name> (<year>2017</year>). <article-title>Integrative clinical genomics of metastatic cancer</article-title>. <source>Nature</source>, <volume>548</volume>(<issue>7667</issue>), <fpage>297</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1038/nature23306</pub-id><pub-id pub-id-type="pmid">28783718</pub-id><pub-id pub-id-type="pmcid">PMC5995337</pub-id></mixed-citation></ref><ref id="R91"><mixed-citation publication-type="journal"><name name-style="western"><surname>Robinson</surname><given-names>M. D.</given-names></name>, &amp; <name name-style="western"><surname>Oshlack</surname><given-names>A.</given-names></name> (<year>2010</year>). <article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title>. <source>Genome Biology</source>, <volume>11</volume>(<issue>3</issue>). <pub-id pub-id-type="doi">10.1186/gb-2010-11-3-r25</pub-id><pub-id pub-id-type="pmcid">PMC2864565</pub-id><pub-id pub-id-type="pmid">20196867</pub-id></mixed-citation></ref><ref id="R92"><mixed-citation publication-type="journal"><name name-style="western"><surname>Roche</surname><given-names>P. A.</given-names></name>, &amp; <name name-style="western"><surname>Furuta</surname><given-names>K.</given-names></name> (<year>2015</year>). <article-title>The ins and outs of MHC class II-mediated antigen processing and presentation</article-title>. <source>Nature Reviews. Immunology</source>, <volume>15</volume>(<issue>4</issue>), <fpage>203</fpage>&#8211;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1038/nri3818</pub-id><pub-id pub-id-type="pmcid">PMC6314495</pub-id><pub-id pub-id-type="pmid">25720354</pub-id></mixed-citation></ref><ref id="R93"><mixed-citation publication-type="journal"><name name-style="western"><surname>Rosenberg</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Hoffman-Censits</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Powles</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>van der Heijden</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Balar</surname><given-names>A. v</given-names></name>, <name name-style="western"><surname>Necchi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Dawson</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>O&#8217;Donnell</surname><given-names>P. H.</given-names></name>, <name name-style="western"><surname>Balmanoukian</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Loriot</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Srinivas</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Retz</surname><given-names>M. M.</given-names></name>, <name name-style="western"><surname>Grivas</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Joseph</surname><given-names>R. W.</given-names></name>, <name name-style="western"><surname>Galsky</surname><given-names>M. D.</given-names></name>, <name name-style="western"><surname>Fleming</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Petrylak</surname><given-names>D. P.</given-names></name>, <name name-style="western"><surname>Perez-Gracia</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Burris</surname><given-names>H. A.</given-names></name>, &#8230; <name name-style="western"><surname>Dreicer</surname><given-names>R.</given-names></name> (<year>2016</year>). <article-title>Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial</article-title>. <source>Lancet (London, England)</source>, <volume>387</volume>(<issue>10031</issue>), <fpage>1909</fpage>&#8211;<lpage>1920</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00561-4</pub-id><pub-id pub-id-type="pmid">26952546</pub-id><pub-id pub-id-type="pmcid">PMC5480242</pub-id></mixed-citation></ref><ref id="R94"><mixed-citation publication-type="journal"><name name-style="western"><surname>Rozeman</surname><given-names>E. A.</given-names></name>, <name name-style="western"><surname>Hoefsmit</surname><given-names>E. P.</given-names></name>, <name name-style="western"><surname>Reijers</surname><given-names>I. L. M.</given-names></name>, <name name-style="western"><surname>Saw</surname><given-names>R. P. M.</given-names></name>, <name name-style="western"><surname>Versluis</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Krijgsman</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Dimitriadis</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Sikorska</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>van de Wiel</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Eriksson</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Torres Acosta</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grijpink-Ongering</surname><given-names>L. G.</given-names></name>, <name name-style="western"><surname>Shannon</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Haanen</surname><given-names>J. B. A. G.</given-names></name>, <name name-style="western"><surname>Stretch</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ch&#8217;ng</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Nieweg</surname><given-names>O. E.</given-names></name>, <name name-style="western"><surname>Mallo</surname><given-names>H. A.</given-names></name>, &#8230; <name name-style="western"><surname>Blank</surname><given-names>C. U.</given-names></name> (<year>2021</year>). <article-title>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma</article-title>. <source>Nature Medicine</source>, <volume>27</volume>(<issue>2</issue>), <fpage>256</fpage>&#8211;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-01211-7</pub-id><pub-id pub-id-type="pmid">33558721</pub-id></mixed-citation></ref><ref id="R95"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sade-Feldman</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>Y. J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J. H.</given-names></name>, <name name-style="western"><surname>Rooney</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Barzily-Rokni</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Eliane</surname><given-names>J.-P.</given-names></name>, <name name-style="western"><surname>Bjorgaard</surname><given-names>S. L.</given-names></name>, <name name-style="western"><surname>Hammond</surname><given-names>M. R.</given-names></name>, <name name-style="western"><surname>Vitzthum</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Blackmon</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Frederick</surname><given-names>D. T.</given-names></name>, <name name-style="western"><surname>Hazar-Rethinam</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nadres</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>van Seventer</surname><given-names>E. E.</given-names></name>, <name name-style="western"><surname>Shukla</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Yizhak</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Rosebrock</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Livitz</surname><given-names>D.</given-names></name>, &#8230; <name name-style="western"><surname>Hacohen</surname><given-names>N.</given-names></name> (<year>2017</year>). <article-title>Resistance to checkpoint blockade therapy through inactivation of antigen presentation</article-title>. <source>Nature Communications</source>, <volume>8</volume>(<issue>1</issue>), <fpage>1136</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-01062-w</pub-id><pub-id pub-id-type="pmcid">PMC5656607</pub-id><pub-id pub-id-type="pmid">29070816</pub-id></mixed-citation></ref><ref id="R96"><mixed-citation publication-type="journal"><name name-style="western"><surname>Schaer</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Beckmann</surname><given-names>R. P.</given-names></name>, <name name-style="western"><surname>Dempsey</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Huber</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Forest</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Amaladas</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y. C.</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>E. R.</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Capen</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Carpenito</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Staschke</surname><given-names>K. A.</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>L. A.</given-names></name>, <name name-style="western"><surname>Litchfield</surname><given-names>L. M.</given-names></name>, <name name-style="western"><surname>Merzoug</surname><given-names>F. F.</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Iversen</surname><given-names>P. W.</given-names></name>, <name name-style="western"><surname>Buchanan</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Kalos</surname><given-names>M.</given-names></name> (<year>2018</year>). <article-title>The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade</article-title>. <source>Cell Reports</source>, <volume>22</volume>(<issue>11</issue>), <fpage>2978</fpage>&#8211;<lpage>2994</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.02.053</pub-id><pub-id pub-id-type="pmid">29539425</pub-id></mixed-citation></ref><ref id="R97"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sehgal</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>R. R.</given-names></name>, <name name-style="western"><surname>Widick</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Bindal</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>D. C.</given-names></name>, <name name-style="western"><surname>Shea</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rangachari</surname><given-names>D.</given-names></name>, &amp; <name name-style="western"><surname>Costa</surname><given-names>D. B.</given-names></name> (<year>2021</year>). <article-title>Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy</article-title>. <source>JAMA Network Open</source>, <volume>4</volume>(<issue>2</issue>), <fpage>e2037120</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.37120</pub-id><pub-id pub-id-type="pmid">33570575</pub-id><pub-id pub-id-type="pmcid">PMC7879233</pub-id></mixed-citation></ref><ref id="R98"><mixed-citation publication-type="journal"><name name-style="western"><surname>Semeraro</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Parrinello</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Cancarini</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pasquini</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zarra</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Cimino</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Cancarini</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Valentini</surname><given-names>U.</given-names></name>, &amp; <name name-style="western"><surname>Costagliola</surname><given-names>C.</given-names></name> (<year>2011</year>). <article-title>Predicting the risk of diabetic retinopathy in type 2 diabetic patients</article-title>. <source>Journal of Diabetes and Its Complications</source>, <volume>25</volume>(<issue>5</issue>), <fpage>292</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdiacomp.2010.12.002</pub-id><pub-id pub-id-type="pmid">21334925</pub-id></mixed-citation></ref><ref id="R99"><mixed-citation publication-type="book"><name name-style="western"><surname>Shapley</surname><given-names>L. S.</given-names></name> (<year>1953</year>). <part-title>A Value for n-person Games</part-title>. <source>In Contributions to the Theory of Games (AM-28), Volume II</source> (pp. <fpage>307</fpage>&#8211;<lpage>318</lpage>). <publisher-name>Princeton University Press</publisher-name>.</mixed-citation></ref><ref id="R100"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sheng</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>LaFleur</surname><given-names>M. W.</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>T. H.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chakravarthy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Conway</surname><given-names>J. R.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>P.-H.</given-names></name>, <name name-style="western"><surname>van Allen</surname><given-names>E. M.</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>G. J.</given-names></name>, <name name-style="western"><surname>de Carvalho</surname><given-names>D. D.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>H. H.</given-names></name>, <name name-style="western"><surname>Sharpe</surname><given-names>A. H.</given-names></name>, &amp; <name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name> (<year>2018</year>). <article-title>LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade</article-title>. <source>Cell</source>, <volume>174</volume>(<issue>3</issue>), <fpage>549</fpage>&#8211;<lpage>563.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.05.052</pub-id><pub-id pub-id-type="pmid">29937226</pub-id><pub-id pub-id-type="pmcid">PMC6063761</pub-id></mixed-citation></ref><ref id="R101"><mixed-citation publication-type="book"><name name-style="western"><surname>Sievert</surname><given-names>C.</given-names></name> (<year>2020</year>). <source>Interactive Web-Based Data Visualization with R, plotly, and shiny</source>. <publisher-name>Chapman and Hall/CRC</publisher-name>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plotly-r.com" ext-link-type="uri">https://plotly-r.com</ext-link></comment></mixed-citation></ref><ref id="R102"><mixed-citation publication-type="journal"><name name-style="western"><surname>Snider</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>L. N.</given-names></name>, <name name-style="western"><surname>Lemmers</surname><given-names>R. J. L. F.</given-names></name>, <name name-style="western"><surname>Kyba</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ware</surname><given-names>C. B.</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Tawil</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Filippova</surname><given-names>G. N.</given-names></name>, <name name-style="western"><surname>van der Maarel</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Tapscott</surname><given-names>S. J.</given-names></name>, &amp; <name name-style="western"><surname>Miller</surname><given-names>D. G.</given-names></name> (<year>2010</year>). <article-title>Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene</article-title>. <source>PLoS Genetics</source>, <volume>6</volume>(<issue>10</issue>), <fpage>e1001181</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1001181</pub-id><pub-id pub-id-type="pmid">21060811</pub-id><pub-id pub-id-type="pmcid">PMC2965761</pub-id></mixed-citation></ref><ref id="R103"><mixed-citation publication-type="journal"><name name-style="western"><surname>Spens</surname><given-names>A. E.</given-names></name>, <name name-style="western"><surname>Sutliff</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>S. R.</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>A. E.</given-names></name>, &amp; <name name-style="western"><surname>Tapscott</surname><given-names>S. J.</given-names></name> (<year>2023</year>). <article-title>Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit interferon-stimulated gene induction</article-title>. <source>ELife</source>, <volume>12</volume>. <pub-id pub-id-type="doi">10.7554/eLife.82057</pub-id><pub-id pub-id-type="pmcid">PMC10195082</pub-id><pub-id pub-id-type="pmid">37092726</pub-id></mixed-citation></ref><ref id="R104"><mixed-citation publication-type="journal"><name name-style="western"><surname>Spranger</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>R.</given-names></name>, &amp; <name name-style="western"><surname>Gajewski</surname><given-names>T. F.</given-names></name> (<year>2015</year>). <article-title>Melanoma-intrinsic &#946;-catenin signalling prevents anti-tumour immunity</article-title>. <source>Nature</source>, <volume>523</volume>(<issue>7559</issue>), <fpage>231</fpage>&#8211;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1038/nature14404</pub-id><pub-id pub-id-type="pmid">25970248</pub-id></mixed-citation></ref><ref id="R105"><mixed-citation publication-type="journal"><name name-style="western"><surname>Steimle</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Otten</surname><given-names>L. A.</given-names></name>, <name name-style="western"><surname>Zufferey</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Mach</surname><given-names>B.</given-names></name> (<year>1993</year>). <article-title>Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)</article-title>. <source>Cell</source>, <volume>75</volume>(<issue>1</issue>), <fpage>135</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="pmid">8402893</pub-id></mixed-citation></ref><ref id="R106"><mixed-citation publication-type="journal"><name name-style="western"><surname>Steimle</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Siegrist</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Mottet</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lisowska-Grospierre</surname><given-names>B.</given-names></name>, &amp; <name name-style="western"><surname>Mach</surname><given-names>B.</given-names></name> (<year>1994</year>). <article-title>Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA</article-title>. <source>Science (New York, N.Y.)</source>, <volume>265</volume>(<issue>5168</issue>), <fpage>106</fpage>&#8211;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1126/science.8016643</pub-id><pub-id pub-id-type="pmid">8016643</pub-id></mixed-citation></ref><ref id="R107"><mixed-citation publication-type="journal"><name name-style="western"><surname>Stein</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Paschold</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Tintelnot</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Goekkurt</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Henkes</surname><given-names>S.-S.</given-names></name>, <name name-style="western"><surname>Simnica</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Schultheiss</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Willscher</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wickenhauser</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Thuss-Patience</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lorenzen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ettrich</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Riera-Knorrenschild</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jacobasch</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kretzschmar</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kubicka</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Al-Batran</surname><given-names>S.-E.</given-names></name>, <name name-style="western"><surname>Reinacher-Schick</surname><given-names>A.</given-names></name>, &#8230; <name name-style="western"><surname>Binder</surname><given-names>M.</given-names></name> (<year>2022</year>). <article-title>Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial</article-title>. <source>JAMA Oncology</source>, <volume>8</volume>(<issue>8</issue>), <fpage>1150</fpage>&#8211;<lpage>1158</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2228</pub-id><pub-id pub-id-type="pmid">35737383</pub-id><pub-id pub-id-type="pmcid">PMC9227706</pub-id></mixed-citation></ref><ref id="R108"><mixed-citation publication-type="journal"><name name-style="western"><surname>&#352;trumbelj</surname><given-names>E.</given-names></name>, &amp; <name name-style="western"><surname>Kononenko</surname><given-names>I.</given-names></name> (<year>2014</year>). <article-title>Explaining prediction models and individual predictions with feature contributions</article-title>. <source>Knowledge and Information Systems</source>, <volume>41</volume>(<issue>3</issue>), <fpage>647</fpage>&#8211;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1007/s10115-013-0679-x</pub-id></mixed-citation></ref><ref id="R109"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sucker</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Pieper</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Heeke</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Maltaner</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Stadtler</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Real</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Bielefeld</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Howe</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Weide</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Gutzmer</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Utikal</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Loquai</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Gogas</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Klein-Hitpass</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zeschnigk</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Westendorf</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Trilling</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>S.</given-names></name>, &#8230; <name name-style="western"><surname>Paschen</surname><given-names>A.</given-names></name> (<year>2017</year>). <article-title>Acquired IFN&#947; resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions</article-title>. <source>Nature Communications</source>, <volume>8</volume>, <fpage>15440</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms15440</pub-id><pub-id pub-id-type="pmcid">PMC5460020</pub-id><pub-id pub-id-type="pmid">28561041</pub-id></mixed-citation></ref><ref id="R110"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sucker</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Real</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Heeke</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bielefeld</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Ma&#946;en</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Moll</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Maltaner</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Schilling</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Sabbatino</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Lennerz</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Kloor</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ferrone</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>Griewank</surname><given-names>K.</given-names></name>, &amp; <name name-style="western"><surname>Paschen</surname><given-names>A.</given-names></name> (<year>2014</year>). <article-title>Genetic evolution of T-cell resistance in the course of melanoma progression</article-title>. <source>Clinical Cancer Research : An Official Journal of the American Association for Cancer Research</source>, <volume>20</volume>(<issue>24</issue>), <fpage>6593</fpage>&#8211;<lpage>6604</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0567</pub-id><pub-id pub-id-type="pmid">25294904</pub-id><pub-id pub-id-type="pmcid">PMC8728890</pub-id></mixed-citation></ref><ref id="R111"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sugie</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Funaya</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kawamura</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>M. G.</given-names></name>, &amp; <name name-style="western"><surname>Aoki</surname><given-names>F.</given-names></name> (<year>2020</year>). <article-title>Expression of Dux family genes in early preimplantation embryos</article-title>. <source>Scientific Reports</source>, <volume>10</volume>(<issue>1</issue>), <fpage>19396</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-76538-9</pub-id><pub-id pub-id-type="pmid">33173118</pub-id><pub-id pub-id-type="pmcid">PMC7655946</pub-id></mixed-citation></ref><ref id="R112"><mixed-citation publication-type="journal"><name name-style="western"><surname>Sullivan</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Infante</surname><given-names>J. R.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>M. R.</given-names></name>, <name name-style="western"><surname>Hodi</surname><given-names>F. S.</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>K. D.</given-names></name>, <name name-style="western"><surname>Tawbi</surname><given-names>H. A.</given-names></name>, <name name-style="western"><surname>Hernandez</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wongchenko</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ballinger</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Cha</surname><given-names>E.</given-names></name>, &amp; <name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name> (<year>2019</year>). <article-title>Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients</article-title>. <source>Nature Medicine</source>, <volume>25</volume>(<issue>6</issue>), <fpage>929</fpage>&#8211;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0474-7</pub-id><pub-id pub-id-type="pmid">31171876</pub-id></mixed-citation></ref><ref id="R113"><mixed-citation publication-type="journal"><name name-style="western"><surname>Tawbi</surname><given-names>H. A.</given-names></name>, <name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Lipson</surname><given-names>E. J.</given-names></name>, <name name-style="western"><surname>Ascierto</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Matamala</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Castillo Guti&#233;rrez</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Gogas</surname><given-names>H. J.</given-names></name>, <name name-style="western"><surname>Lao</surname><given-names>C. D.</given-names></name>, <name name-style="western"><surname>de Menezes</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Dalle</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Arance</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Abaskharoun</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Keidel</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Simonsen</surname><given-names>K. L.</given-names></name>, <name name-style="western"><surname>Sobiesk</surname><given-names>A. M.</given-names></name>, &#8230; <collab>RELATIVITY-047 Investigators</collab>. (<year>2022</year>). <article-title>Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma</article-title>. <source>The New England Journal of Medicine</source>, <volume>386</volume>(<issue>1</issue>), <fpage>24</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2109970</pub-id><pub-id pub-id-type="pmid">34986285</pub-id><pub-id pub-id-type="pmcid">PMC9844513</pub-id></mixed-citation></ref><ref id="R114"><mixed-citation publication-type="webpage"><name name-style="western"><surname>Therneau</surname><given-names>T.</given-names></name> (<year>2022</year>). <source>A Package for Survival Analysis in R (R package version 3.4&#8211;0)</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=survival" ext-link-type="uri">https://CRAN.R-project.org/package=survival</ext-link></comment></mixed-citation></ref><ref id="R115"><mixed-citation publication-type="book"><name name-style="western"><surname>Therneau</surname><given-names>T. M.</given-names></name>, &amp; <name name-style="western"><surname>Grambsch</surname><given-names>P. M.</given-names></name> (<year>2000</year>). <source>Modeling Survival Data: Extending the Cox Model</source>. <publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc>. <pub-id pub-id-type="doi">10.1007/978-1-4757-3294-8</pub-id></mixed-citation></ref><ref id="R116"><mixed-citation publication-type="journal"><name name-style="western"><surname>Thorvaldsd&#243;ttir</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>J. T.</given-names></name>, &amp; <name name-style="western"><surname>Mesirov</surname><given-names>J. P.</given-names></name> (<year>2013</year>). <article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title>. <source>Briefings in Bioinformatics</source>, <volume>14</volume>(<issue>2</issue>), <fpage>178</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id><pub-id pub-id-type="pmcid">PMC3603213</pub-id></mixed-citation></ref><ref id="R117"><mixed-citation publication-type="journal"><name name-style="western"><surname>Trapnell</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pachter</surname><given-names>L.</given-names></name>, &amp; <name name-style="western"><surname>Salzberg</surname><given-names>S. L.</given-names></name> (<year>2009</year>). <article-title>TopHat: Discovering splice junctions with RNA-Seq</article-title>. <source>Bioinformatics</source>, <volume>25</volume>(<issue>9</issue>), <fpage>1105</fpage>&#8211;<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp120</pub-id><pub-id pub-id-type="pmid">19289445</pub-id><pub-id pub-id-type="pmcid">PMC2672628</pub-id></mixed-citation></ref><ref id="R118"><mixed-citation publication-type="journal"><name name-style="western"><surname>Whiddon</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Langford</surname><given-names>A. T.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>C.-J.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>J. W.</given-names></name>, &amp; <name name-style="western"><surname>Tapscott</surname><given-names>S. J.</given-names></name> (<year>2017</year>). <article-title>Conservation and innovation in the DUX4-family gene network</article-title>. <source>Nature Genetics</source>, <volume>49</volume>(<issue>6</issue>), <fpage>935</fpage>&#8211;<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3846</pub-id><pub-id pub-id-type="pmid">28459454</pub-id><pub-id pub-id-type="pmcid">PMC5446306</pub-id></mixed-citation></ref><ref id="R119"><mixed-citation publication-type="book"><name name-style="western"><surname>Wickham</surname><given-names>H.</given-names></name> (<year>2016</year>). <source>ggplot2: Elegant Graphics for Data Analysis</source>. <publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ggplot2.tidyverse.org" ext-link-type="uri">https://ggplot2.tidyverse.org</ext-link></comment></mixed-citation></ref><ref id="R120"><mixed-citation publication-type="webpage"><name name-style="western"><surname>Wickham</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Fran&#231;ois</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>L.</given-names></name>, &amp; <name name-style="western"><surname>M&#252;ller</surname><given-names>K.</given-names></name> (<year>2022</year>). <source>dplyr: A Grammar of Data Manipulation (R package version 1.0.10)</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://CRAN.R-project.org/package=dplyr" ext-link-type="uri">https://CRAN.R-project.org/package=dplyr</ext-link></comment></mixed-citation></ref><ref id="R121"><mixed-citation publication-type="journal"><name name-style="western"><surname>Wolf</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Bartok</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Patkar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Eli</surname><given-names>G. B.</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Litchfield</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Jim&#233;nez-S&#225;nchez</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Trabish</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J. S.</given-names></name>, <name name-style="western"><surname>Karathia</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Barnea</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>C.-P.</given-names></name>, <name name-style="western"><surname>Cinnamon</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Solomon</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bitton</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>P&#233;rez-Guijarro</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Dubovik</surname><given-names>T.</given-names></name>, &#8230; <name name-style="western"><surname>Samuels</surname><given-names>Y.</given-names></name> (<year>2019</year>). <article-title>UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma</article-title>. <source>Cell</source>, <volume>179</volume>(<issue>1</issue>), <fpage>219</fpage>&#8211;<lpage>235.e21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.032</pub-id><pub-id pub-id-type="pmid">31522890</pub-id><pub-id pub-id-type="pmcid">PMC6863386</pub-id></mixed-citation></ref><ref id="R122"><mixed-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bo</surname><given-names>X.</given-names></name>, &amp; <name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name> (<year>2021</year>). <article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title>. <source>Innovation (Cambridge (Mass.))</source>, <volume>2</volume>(<issue>3</issue>), <fpage>100141</fpage>. <pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id></mixed-citation></ref><ref id="R123"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yasuda</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tsuzuki</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kawazu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hayakawa</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Kojima</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Imoto</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kohsaka</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kunita</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Doi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Sakura</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yujiri</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Fujimaki</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Aoyama</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ohtake</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Takita</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sai</surname><given-names>E.</given-names></name>, &#8230; <name name-style="western"><surname>Mano</surname><given-names>H.</given-names></name> (<year>2016</year>). <article-title>Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults</article-title>. <source>Nature Genetics</source>, <volume>48</volume>(<issue>5</issue>), <fpage>569</fpage>&#8211;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3535</pub-id><pub-id pub-id-type="pmid">27019113</pub-id></mixed-citation></ref><ref id="R124"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kodaira</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kawamoto</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yoshimoto</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Endo</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Kodama</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kushima</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hiraoka</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Motoi</surname><given-names>T.</given-names></name>, &amp; <name name-style="western"><surname>Kawai</surname><given-names>A.</given-names></name> (<year>2016</year>). <article-title>CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas</article-title>. <source>The American Journal of Surgical Pathology</source>, <volume>40</volume>(<issue>3</issue>), <fpage>313</fpage>&#8211;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000000570</pub-id><pub-id pub-id-type="pmid">26685084</pub-id></mixed-citation></ref><ref id="R125"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoshimoto</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chilton-MacNeill</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Shago</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Squire</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zielenska</surname><given-names>M.</given-names></name>, &amp; <name name-style="western"><surname>Somers</surname><given-names>G. R.</given-names></name> (<year>2009</year>). <article-title>Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event</article-title>. <source>Cancer Genetics and Cytogenetics</source>, <volume>195</volume>(<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.cancergencyto.2009.06.015</pub-id><pub-id pub-id-type="pmid">19837261</pub-id></mixed-citation></ref><ref id="R126"><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.-G.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>, &amp; <name name-style="western"><surname>He</surname><given-names>Q.-Y.</given-names></name> (<year>2012</year>). <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source>Omics : A Journal of Integrative Biology</source>, <volume>16</volume>(<issue>5</issue>), <fpage>284</fpage>&#8211;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id></mixed-citation></ref><ref id="R127"><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name>, &amp; <name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name> (<year>2018</year>). <article-title>Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity</article-title>. <source>Nature Immunology</source>, <volume>19</volume>(<issue>7</issue>), <fpage>723</fpage>&#8211;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-018-0132-0</pub-id><pub-id pub-id-type="pmid">29915296</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><title><italic toggle="yes">DUX4</italic> is frequently expressed in diverse metastatic cancers.</title><p id="P43">(<bold>A</bold>) Matched The Cancer Genome Atlas (gray, TCGA) and advanced metastatic (orange) cancer datasets analyzed in our study.</p><p id="P44">(<bold>B</bold>) The proportion of <italic toggle="yes">DUX4</italic>-expressing cancers in TCGA (purple shading) and metastatic (red shading) cancers. The blue line indicates the median over TCGA cancer cohorts. The 95% confidence intervals were estimated via a two-sided proportion test.</p><p id="P45">(<bold>C</bold>) <italic toggle="yes">DUX4</italic> expression values (TPM, transcripts per million) in TCGA (purple shading) and advanced metastatic (red shading) cancer cohorts analyzed in our study.</p><p id="P46">(<bold>D</bold>) Representative RNA-seq coverage plots from primary and metastatic cancers for reads mapping to the <italic toggle="yes">DUX4</italic> cDNA. Open reading frame (ORF, black rectangle); UTR (untranslated region, gray line); Homeobox domains (yellow rectangles).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.07.10.548412v2-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><title><italic toggle="yes">DUX4</italic> expression in advanced cancers is associated with signatures of host anti-tumor immunity inhibition.</title><p id="P47">(<bold>A</bold>) Gene Ontology (GO) enrichment network analysis of <italic toggle="yes">DUX4</italic>-downregulated genes. Differentially expressed genes were identified from the comparison of advanced urothelial carcinoma tumors with high (&gt; 1 TPM) vs. low (&#8804; 1 TPM) <italic toggle="yes">DUX4</italic> expression. The nodes and node sizes correspond to significantly enriched GO terms (Benjamini-Hochberg-adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) and the number of <italic toggle="yes">DUX4</italic>-downregulated genes in each, respectively. The edges connecting nodes indicate shared genes.</p><p id="P48">(<bold>B</bold>) Downregulated (blue) and upregulated (red) anti-tumor immunity genes in tumors with <italic toggle="yes">DUX4</italic>-positive (&gt; 1 TPM) vs. -negative (&#8804; 1 TPM) advanced urothelial carcinomas.</p><p id="P49">(<bold>C</bold>) Effector CD8<sup>+</sup> T cell score, defined as the mean of the z-score normalized gene expression values in the signature (<xref rid="R71" ref-type="bibr">Mariathasan et al., 2018</xref>) for <italic toggle="yes">DUX4</italic>+/&#8722; tumors. The <italic toggle="yes">p</italic>-value was estimated via a Mann-Whitney <italic toggle="yes">U</italic> test.</p><p id="P50">(<bold>D</bold>) <italic toggle="yes">CXCL9</italic> expression for <italic toggle="yes">DUX4</italic>+/&#8722; tumors. The <italic toggle="yes">p</italic>-value was estimated via a Mann-Whitney <italic toggle="yes">U</italic> test.</p><p id="P51">(<bold>E</bold>) As in (D), but illustrating <italic toggle="yes">CXCL10</italic> expression.</p><p id="P52">(<bold>F</bold>) Proportion of immune phenotypes in <italic toggle="yes">DUX4</italic>+/&#8722; cancers. The phenotypes were based on the CD8<sup>+</sup> T cell abundance and degree of tumor infiltration determined by anti-CD8 staining of tumor FFPE sections in the original study (<xref rid="R71" ref-type="bibr">Mariathasan et al., 2018</xref>). The <italic toggle="yes">p</italic>-value was estimated via a multinomial proportion test.</p><p id="P53">(<bold>G</bold>) PD-L1-expression on tumor cells stratified by <italic toggle="yes">DUX4</italic> expression status measured by immunohistochemistry in the original study. The samples were categorized based on the percentage of PD-L1-positive tumor cells. The <italic toggle="yes">p</italic>-value was estimated via a multinomial proportion test.</p><p id="P54">(<bold>H</bold>) As in (G), but PD-L1 staining on tumor-infiltrating immune cells (lymphocytes, macrophages, and dendritic cells) is represented.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.07.10.548412v2-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><title><italic toggle="yes">DUX4</italic>-positivity is associated with decreased response to immune checkpoint inhibition.</title><p id="P55">(<bold>A</bold>) The proportion of clinical response classifications (RECIST, Response Evaluation Criteria in Solid Tumors) in <italic toggle="yes">DUX4</italic>-positive (<italic toggle="yes">DUX4</italic>+, &gt; 1 TPM) or -negative (<italic toggle="yes">DUX4</italic>&#8722;, &#8804; 1 TPM) advanced urothelial carcinoma patients. RECIST categories were assigned in the original study (<xref rid="R71" ref-type="bibr">Mariathasan et al., 2018</xref>). The <italic toggle="yes">p</italic>-value was estimated via a multinomial proportion test.</p><p id="P56">(<bold>B</bold>) Kaplan-Meier (KM) estimates of overall survival for the patients in (A) stratified by tumor mutational burden (TMB, number of missense mutations). The estimated survival functions (solid lines), censored events (crosses), and 95% confidence intervals (transparent ribbons) for the patients in the top and bottom TMB quartiles are plotted. The <italic toggle="yes">p</italic>-value was estimated via a log-rank test.</p><p id="P57">(<bold>C</bold>) As in (B), but patients are stratified by <italic toggle="yes">DUX4</italic> expression. To control for possible confounding by TMB, the quartile of patients with the lowest TMB was excluded.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.07.10.548412v2-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><title>DUX4 expression status affects clinical response after controlling for other genetic and clinical variables.</title><p id="P58">(<bold>A</bold>) Hazard ratios (HR) and 95% confidence intervals for the variables included in univariate (left) or multivariate (right) Cox Proportional Hazards (PH) regression. For categorical variables, the reference groups are indicated by points at HR = 1. Statistically significant predictors that are associated with increased (orange) or decreased (blue) risk in both the univariate and multivariate contexts are highlighted. ECOG (Eastern Cooperative Oncology Group); BCG (Bacillus Calmette-Guerin).</p><p id="P59">(<bold>B</bold>) Bayesian information criterion (BIC) measurements for goodness of fit for the full (TMB, Clinical, DUX4 expression) vs. reduced Cox PH models, where lower values indicate better fit. The bootstrapped BIC mean and the 95% confidence interval are illustrated. Clinical (ECOG Performance Status and Platinum treatment history).</p><p id="P60">(<bold>C</bold>) Kaplan-Meier (KM) estimates of overall survival, 95% confidence interval (transparent ribbon), and censored events (crosses) for low-risk (solid gray line) and high-risk (solid orange line) patients in the training (left) and test (right) sets. Risk group assignments were based on risk scores estimated by the full Cox PH model. <italic toggle="yes">p</italic>-values were estimated via a log-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.07.10.548412v2-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><title><italic toggle="yes">DUX4</italic> expression is associated with decreased overall survival in the context of immune checkpoint inhibition.</title><p id="P61">(<bold>A</bold>) Random Survival Forest (RSF) predicted overall survival for patients with either <italic toggle="yes">DUX4-</italic>positive or -negative tumors in the training and test sets. Out-of-bag (OOB) survival predictions are shown for the patients in the training set. Survival predictions for individual patients (thin lines) and the median survival function across the cohort (thick line) are represented. <italic toggle="yes">DUX4</italic>&#8722; (&lt; 0.25 TPM); <italic toggle="yes">DUX4</italic>+ (&gt; 1 TPM).</p><p id="P62">(<bold>B</bold>) Training (OOB) and test set survival probability predictions for patients with <italic toggle="yes">DUX4</italic>+/&#8722; tumors at 12 and 18 months. The <italic toggle="yes">p</italic>-values were estimated using a two-sided Mann-Whitney <italic toggle="yes">U</italic> test.</p><p id="P63">(<bold>C</bold>) Survival probability for patients in the training and test sets. Survival functions corresponding to the median RSF prediction (solid orange line) and the Kaplan-Meier estimate (dashed gray) are displayed.</p><p id="P64">(<bold>D</bold>) Feature importance for variables used in the RSF model. The average absolute estimated Shapley values (solid lines) are shown, associated with predicting survival probability at particular times. The 95% confidence interval of the mean (transparent ribbon) is plotted.</p><p id="P65">(<bold>E</bold>) Surface plot showing adjusted (marginal) survival probability, measured via partial dependence, as a function of tumor mutational burden (TMB, number of missense mutations) and time. Each point on the surface corresponds to the mean survival prediction (at the respective timepoint) after TMB is fixed to the respective value for all patients.</p><p id="P66">(<bold>F</bold>) Partial plot showing adjusted survival probability as a function of <italic toggle="yes">DUX4</italic> expression status. The median survival probability (solid lines) and the 95% confidence interval (transparent ribbon) after <italic toggle="yes">DUX4</italic> expression status is fixed to the indicated value for all patients are plotted.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2023.07.10.548412v2-f0005.jpg"/></fig></floats-group></article></pmc-articleset>